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Zusammenfassung in deutscher Sprache  
 
Die Hüftkopfnekrose – eine retrospektive Auswertung gelenkerhaltender 
Therapiemöglichkeiten und ein Ausblick auf zukünftige klinische Möglichkeiten 
 
Einleitung: 
Die hier vorliegende Arbeit zur aseptischen Hüftkopfnekrose des Erwachsenen gliedert 
sich im Wesentlichen in zwei große Teile. Im ersten Teil wird ein umfangreicher und 
vollständiger Überblick über die aktuellsten klinischen und wissenschaftlichen 
Erkenntnisse zur Ätiologie, Diagnostik und Therapie in der gängigen Fachliteratur 
gegeben.   
Im zweiten Teil, welcher sich wiederum in drei Abschnitte, gliedert werden die selbst 
angestellten klinischen und wissenschaftlichen Untersuchungen, sowie deren Ergebnisse 
präsentiert. 
 
Die Femurkopfnekrose ist eine Erkrankung, welche vor allem jüngere Menschen, 
zwischen 30 und 50 Jahren und somit in Mitten ihrer größten Leistungsfähigkeit betrifft. 
Dies hat nicht nur für jeden Betroffenen individuell belastende und einschränkende 
Auswirkungen, sondern ist auch für die Gesellschaft und das Gesundheitssystem eine 
enorme Belastung [1] [2]. Die aseptische Nekrose des Hüftkopfes beginnt langsam und 
verläuft unbehandelt progredient bis zur vollständigen arthrotischen Zerstörung des 
Gelenkes. Die Patienten berichten in vielen Fällen über eine zunehmende diffuse 
Schmerzhaftigkeit und Bewegungseinschränkung des betroffenen Hüftgelenkes [3]. Die 
treffende Diagnose wird oft erst spät und somit in bereits fortgeschrittenen Stadien 
gestellt. Den diagnostischen Goldstandard stellt die Magnetresonanztomographie (MRT) 
dar. Mittels MRT können bereits die Frühformen der Osteonekrose erkannt werden, wenn 
das normale Röntgenbild noch völlig unauffällig erscheint [4].  
Es haben sich verschiedene Stadien-Klassifikationen der Hüftkopfnekrose entwickelt. Die 
weitaus geläufigste ist hierbei diejenige der „Association Research Circulation Osseous“ 
(ARCO). Diese berücksichtigt vor allem radiologische Aspekte. Sie ermöglicht eine 
Einteilung in die Stadien I bis IV, wobei im potentiell reversiblen Stadium I nur im MRT 
pathologische Veränderungen sichtbar sind. Im Stadium ARCO II wird auch das normale 
Röntgen positiv, mit vermehrter Sklerosierung des Nekroseareals, bei jedoch völlig 
erhaltener Hüftkopfkontur. Im Stadium III kommt es zu subchondralen Einbrüchen, 
welche sich im Röntgenbild als eine Entrundung des Hüftkopfes darstellen. Das finale 
Stadium IV stellt die vollständige Zerstörung des Gelenkpartners dar [5] [6]. Diese 
Einteilung ist neben  dem akademischen Interesse vor allem für die Therapie von 
höchster Relevanz.    
Obwohl viele Risikofaktoren bekannt sind, ist die exakte Ätiologie der Erkrankung noch 
unklar. Als mögliche Risikofaktoren gelten neben den „Lifestyle-Faktoren“ Rauchen und 
Alkoholabusus, vor allem eine längere oder höher dosierte Therapie mit 
Kortikosteroiden. Desweiteren werden physische Überlastung mit Mikrotraumata, 
metabolische Erkrankungen, wie der Morbus Gaucher und genetische Vorerkrankungen, 
wie die Sichelzellanämie oder Thrombophilien genannt [7] [8].  
Pathomechanismus: 
Der Pathomechanismus der Hüftkopfnekrose war lange Zeit unklar, jedoch scheint sich 
mittlerweile die Theorie eines erhöhten intra-ossären Druckes zu bestätigen [9] [1]. Dabei 
wird davon ausgegangen, dass im erkrankten Femurkopf der intramedulläre Druck 
gesteigert ist. Dies führt zu einer Kompression und in Folge dessen zu einer Obstruktion 
von kleinsten venösen Gefäßen. Dadurch kommt es zu einem gestörten Abfluss des 
Blutes und somit zu einem erhöhten Blutvolumen im Knochenmark. Dies führt wiederum 
zu einer Steigerung des Druckes im spongiösen Knochen. Dieser circulus vitiosus bedingt 
eine Minderversorgung des Knochenmarks mit Sauerstoff und endet letztlich im 
nekrotischen Untergang des Gewebes [10].  
Hintergrund: 
Aus der Pathogenese ergeben sich auch die geläufigsten gelenkerhaltenden Therapien. 
Diese haben als primäre Grundidee den Versuch der Entlastung des gestauten 
Kompartiments, da man sich dadurch eine Normalisierung des Blutflusses und folglich 
eine Regeneration des Gewebes erhofft. Bei erhöhtem intrakompartimentellem Druck 
erfolgt somit nach Ficat und Arlet eine Core Decompression [9]. Das primäre Ziel aller 
Therapieversuche ist in frühen Stadien immer die Erhaltung des Hüftgelenkes. Dies sollte 
wenn möglich dauerhaft sein, jedoch sollte dadurch zumindest Zeit gewonnen werden, 
bis die Implantation einer Totalendoprothese (TEP) nötig wird. Als mögliche 
konservative Therapieoption wird vor allem die Entlastung des betroffenen Gelenkes 
mittels Gehstützen empfohlen, um in der akuten Phase eine weitere Eskalation zu 
fortgeschrittenen Stadien zu vermeiden [5]. Ob eine spontane Remission, allein dadurch 
zustande kommt ist unklar. Auch vielfältige medikamentöse Therapiemöglichkeiten von 
Statinen, über Bisphosphonate, bis hin zu Rheologika, wie das stabile Prostazyklin-
Analogon Ilomedin werden in der klinischen Praxis eingesetzt. Durch das am häufigsten 
angewandte und am besten erforschte Ilomedin erhofft man sich eine Steigerung des 
intramedullären Blutflusses, mit einer konsekutiven Regeneration des Knochengewebes. 
Ilomedin wird intravenös in einem fünf tägigen Schema mit ansteigender 
patientenadaptierter Dosis verabreicht [11]. Es konnte gezeigt werden, dass Patienten, 
welchen das Medikament in den frühen ARCO Stadien I und II verabreicht wurde, eine 
deutliche Reduktion der Schmerzen, eine Zunahme der Mobilität und sogar eine 
radiologische Verbesserung zeigten [12]. Ein großer Vorteil dieser Therapie ist die 
fehlende Invasivität und ihre relativ geringen Nebenwirkungen.  
Als operative gelenkerhaltende Therapie ist die sogenannte „Core Decompression“ am 
weitesten verbreitet und auch am besten untersucht. Hierbei handelt es sich um eine 
Anbohrung des Hüftkopfes, mit dem Ziel der Druckentlastung [13]. Daneben soll durch 
das bewusste Verursachen einer intramedullären Blutung ein Regenerationsreiz gesetzt 
werden. Die Anbohrung erfolgt meistens mittels Kirschnerdrähte, welche unter 
Bildwandlerkontrolle in das nekrotische Areal eingebracht werden. Klassischerweise 
wird die Nekrose fächerförmig angebohrt, um einen größeren Anteil des defekten 
Bereiches zu erfassen [14]. Neben der Anbohrung mit K-Drähten kann dafür auch eine 
etwa zehn Millimeter starke Hohlfräße verwendet werden [15]. Dies eröffnet die 
Möglichkeit das nekrotische Material direkt zu entfernen und bei einer autologen 
Spongiosaplastik durch andernorts gewonnene intakte Spongiosa zu ersetzen [16]. Der 
Nachteil hierbei ist jedoch der größere kortikale Defekt und die damit verbundene 
Schwächung und Frakturgefährdung des Schenkelhalses. Dieses Risiko wird jedoch 
durch eine postoperative Ent- oder Teilbelastung minimiert. Jedoch ist der Eingriff mit 
einem größeren Aufwand verbunden, da hierfür ein zweiter OP-Situs (Beckenkamm) 
geschaffen werden muss. Durch die in der gesunden, durchbluteten Spongiosa 
enthaltenen Osteoprogenitor Zellen erwartet man sich einen zusätzlichen Wachstums- 
und Heilungsstimulus. In der Literatur werden auch weitere autologe 
Knochentransplantate, wie gefäßgestielte Fibula-Transplantate beschrieben [17]. Diese 
konnten sich aber nicht in der breiten Anwendung durchsetzen. Als weitere 
gelenkerhaltende Therapie sind Umstellungsosteotomien zu nennen. Diese sind jedoch 
auf Grund der Komplexizität des Eingriffes und der geringen Patientenakzeptanz eher 
von untergeordneter Bedeutung und speziellen Ausnahmen vorbehalten. Als letzte 
Therapiemöglichkeit bei weit fortgeschrittener Nekrose oder bei Versagen der 
gelenkerhaltenden Optionen bleibt die Hüftgelenkstotalendoprothese (Hüft-TEP) [18]. 
Diese stellt eine sehr gute Therapieform dar, ist bei den überwiegend jungen Patienten 
mit Femurkopfnekrose jedoch so lange wie möglich hinaus zu zögern, um perspektivisch 
häufige Wechsel- und Revisionseingriffe zu vermeiden. 
 
Hauptteil 
Im zweiten Abschnitt der hier vorliegenden Arbeit werden die selbst durchgeführten 
Untersuchungen und Auswertungen dargelegt. Dieser Abschnitt gliedert sich wiederum 
in drei Fragestellungen. Zum ersten wird ein retrospektiver klinischer Vergleich zwischen 
der Anbohrung und der Anbohrung mit autologer Spongiosaplastik angestellt.  
In der zweiten Fragestellung wird die Zielgenauigkeit der beiden Therapievarianten 
untersucht. 
Im dritten Abschnitt erfolgt die Vorstellung einer bisher so noch nicht beschriebenen 
Darstellung der intramedullären Perfusion des Hüftkopfes mittels MRT-basierter 
Perfusionsmessung.  
 
Da in der Literatur viele verschiedene Konzepte zur gelenkerhaltenden Therapie bei 
Hüftkopfnekrose beschrieben werden, soll im ersten Teil der vorliegenden Arbeit ein 
Vergleich zwischen der konventionellen Hüftkopfanbohrung und der Anbohrung mit 
autologer Spongiosaplastik gemacht werden.  
In einem retrospektiven Studiendesign wurden Patienten, welche im orthopädischen 
Universitätsklinikum Bad Abbach gelenkerhaltend therapiert worden waren, 
nachuntersucht. Hierfür wurden aus einem Gesamtkollektiv von 289 Hüften mit der 
Diagnose Hüftkopfnekrose aus dem Zeitraum von 2006 bis 2012 die 62 Fälle mit einer 
gelenkerhaltenden Therapie ausgewählt. Davon konnten 31 Fälle für die 
Nachuntersuchung rekrutiert werden und für die folgenden Untersuchungen 
eingeschlossen werden.  
Die Nachuntersuchung setzte sich zusammen aus einer klinischen Untersuchung, mit 
Ermittlung der Bewegungsfähigkeit (range of motion, ROM), eventuellen Kontrakturen 
und Feststellung der Schmerzhaftigkeit in Ruhe und unter Belastung mittels der visuellen 
Analogskala (VAS 10). Ergänzend wurden die Patienten gebeten einige Fragebögen und 
Scores zu beantworten. Hierbei kamen der Harris Hip Score (HHS), der Hip disability 
and Osteoarthritis Outcome Score (HOOS), der EuroQol-5D (EQ-5D) und der Short 
Form 36 (SF-36) zum Einsatz. Für die radiologische Beurteilung des Hüftgelenkes wurde 
ein konventionelles Röntgen in Hüftübersicht und in der Lauenstein-Projektion 
angefertigt. Hierauf wurde bei allen Patienten eine Magnetresonanztomographie (MRT) 
mit Kontrastmittel durchgeführt. An Hand dieser Daten erfolgte eine Gegenüberstellung 
von jeweils elf Patienten mit Anbohrung oder Anbohrung mit Spongiosaplastik. Diese 
relativ kleine Anzahl an Studienteilnehmern in dieser Subgruppe war vor allem durch den 
Versuch der bestmöglichen Vergleichbarkeit begründet, da durch „matched pairs“ eine 
möglichst homogene Verteilung der Gruppen erreicht werden sollte. Das „matching“ 
erfolgte nach den Parametern Geschlecht und Alter. Außerdem wurden in jeder Gruppe 
nur Patienten berücksichtigt, welche von dem jeweils gleichen Operateur behandelt 
worden waren. Zusätzlich lag bei allen Eingeschlossenen ein initiales ARCO II Stadium 
vor. Die Nachuntersuchung erfolgte im Mittel etwa vier Jahre nach der Intervention in 
der Gruppe der „Core Decompression“ und etwa fünf Jahre nach Therapie bei den 
Patienten die eine autologe Spongiosaplastik erhalten hatten.  
 
Vergleich zwischen Core Decompression und autologer Spongiosaplastik 
Die Analyse der Daten erbrachte zwar keine statistisch signifikanten Unterschiede 
bezüglich der klinischen und radiologischen Ergebnisse  zwischen den beiden Gruppen, 
jedoch generell gute Langzeitergebnisse mit hoher Patientenzufriedenheit. In den 
klinischen Auswertungen des Bewegungsausmaßes der behandelten Hüfte, als Indikator 
für die Funktionalität des Gelenkes und der Schmerzhaftigkeit während Belastung, 
erzielten die Patienten mit einer autologen Spongiosaplastik etwas bessere Ergebnisse. 
Dies spiegelte sich auch in den Angaben der Fragebögen wieder. Dort gaben Patienten 
nach autologer Spongiosaplastik etwas bessere hüftspezifische Werte an. Allerdings war 
das Abschneiden in der Gruppe der reinen Anbohrung etwas besser in Hinblick auf die 
Einschätzung der generellen und psychischen Gesundheit. In der radiologischen 
Beurteilung, also einer erneuten Stadieneinteilung waren im Durchschnitt keine 
Unterschiede feststellbar. Dies bedeutet, dass beide Therapieformen sowohl im 
klinischen, als auch im subjektiven und im radiologischen Outcome sehr ähnlich waren. 
Dies spricht wiederum für die Gleichwertigkeit beider Therapie Optionen.  
 
 
Zielgenauigkeit 
Der zweite Aspekt dieser Arbeit beschäftigt sich mit einer relativ neuen technischen 
Möglichkeit, welche zunehmend Einzug in die operative Medizin erhält. Es geht hierbei 
um die dreidimensionale Rekonstruktion anatomischer oder pathologischer Formationen. 
In der vorliegenden Untersuchung wurden bei 22 angebohrten Hüften die Nekrose und 
der Bohrkanal dreidimensional aus den MRT-Aufnahmen rekonstruiert. Aus der 
Rekonstruktion erfolgte eine Vermessung der Ausmaße und der Volumina der 
nekrotischen Areale. Danach wurden die Abweichungen der jeweiligen Bohrkanäle vom 
Mittelpunkt der Nekrose für jede einzelne Raumachse ausgemessen. Es erfolgte eine 
Gegenüberstellung von zehn Hüften mit reiner Core Decompression gegen 12 Hüften mit 
Spongiosaplastik. Aus den gewonnenen Ergebnissen zeigte sich, dass alle nekrotischen 
Areale von der Anbohrung getroffen wurden. Ein Vergleich der Genauigkeit der 
Intervention zwischen der klassischen Anbohrung und der Anbohrung mit anschließender 
Spongiosaplastik ergab keine statistisch signifikanten Unterschiede zwischen den beiden 
Methoden.  
Im Zuge der Volumenbestimmung der Nekrose konnte der bereits in der Literatur 
beschriebene Zusammenhang zwischen größerem Ausmaß der Nekrose und einer 
wahrscheinlicheren Progredienz der Erkrankung bestätigt werden.  
 
Intramedulläre Perfusionsmessung 
Im dritten Teil dieser Studie wurde das neuartige Verfahren der intramedullären 
Perfusionsmessung untersucht. Das Grundprinzip dieser Methode beruht auf MRT-
Aufnahmen zu bestimmten Zeitintervallen nach  Kontrastmittelapplikation. Hierfür 
wurde den Patienten ein Kontrastmittel injiziert und nach festen Zeiten wurden bestimmte 
MRT-Sequenzen durchgeführt. Die Idee hinter dieser Methode besagt, dass sich die 
Kontrastmittelanreicherung im Knochenmark proportional zur Durchblutung verhält. Das 
heißt, dass sich aus der Signalsteigerung im MRT Rückschlüsse auf die Perfusion ziehen 
lassen müssten. Dieser Abschnitt der Studie wurde als rein deskriptiver Versuch zur 
Anwendbarkeit dieser neuartigen und bisher kaum beschriebenen Methode durchgeführt. 
Dies konnte an 26 der behandelten Hüften erfolgen, unabhängig von der Art der Therapie 
oder dem initialen Stadium. Ergänzend wurden auch die gesunden, beziehungsweise 
unbehandelten Hüften betrachtet. Es ließ sich erkennen, dass Patienten mit einer 
Ilomedin-Infusionstherapie erhöhte Perfusionswerte aufwiesen. Die Bedeutung und 
Zusammenhänge dieser Ergebnisse müssen in weiteren Untersuchungen ebenso dargelegt 
werden, wie die Möglichkeit durch die Perfusionsmessung noch früher Hinweise auf eine 
Störung in der intramedullären Perfusion zu bekommen und damit eine 
Risikoabschätzung für das Auftreten einer avaskulären Knochennekrose.                            
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      1.1       Osteonecrosis of the femoral head (ONFH) 
 
Osteonecrosis of the femoral head (ONFH) is a progressive locally limited disease, due to 
a reduced blood flow in the affected area. The impaired perfusion leads to a gradual 
destruction of the femoral head and thus to an enormous effect on the patient’s lifestyle 
[18]. As there are mostly younger people in the third to fifth decade affected, they are 
forced to change their work and leisure activities [2] [19]. In most cases the necrosis is 
restricted to the weight bearing area of the femoral head. Normally the disease starts 
unnoticed without any pain, but as it progresses most patients suffer from an enormous 
pain during weight bearing and in progressed stages also at rest [20]. Untreated the 
avascular necrosis leads to secondary arthrosis of the hip and to the necessity of total hip 
replacement [21] [22]. The natural course of the disease leads within two or three years to 
a complete joint destruction and in consequence to total hip replacement [23]. 
Synonyms are avascular or aseptic necrosis of the femoral head (AVN).  
It is also possible to distinguish between idiopathic or secondary necrosis. In case of 
secondary necrosis there can be found causes like trauma, metabolic diseases or 
medication. For the idiopathic genesis on the other hand there are no evidential trigger 
factors, although even there can be found certain risk factors [2].   
 
1.2 Epidemiology  
 
In Germany there is a reported prevalence of 5,000 to 7,000 new diseases per year [24]. 
The diagnosis of avascular necrosis of the femoral head accounts for 5 to 12 percent of 
total hip replacements [2]. With about 10,000 to 20,000 new cases per year only in the 
USA it is obvious that ONFH is an important factor in health care systems worldwide 
[20].  
 
In about 50 percent the patients suffer a bilateral involvement and in even 80 percent of 
steroid induced necrosis there is a bilateral affection [9]. 
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1.3 Etiology and risk factors 
 
There is a wide range of different etiological factors for the development of an ONFH.  In 
general it has to be distinguished between a traumatic and a non-traumatic genesis. In 
traumatic conditions with fracture or dislocation of the femoral head the reduced blood 
flow, as a result of structural interruption of the blood vessels is obvious. Nevertheless, 
there are known several risk factors, like steroid medication, alcohol abuse, smoking or 
metabolic diseases [2] [25] [10].  
 
1.3.1 Corticosteroid 
A)  Distribution 
One of the major risk factors is the intake of corticosteroids. Studies showed, that about 
10 to 30 percent of osteonecrosis can be associated with steroid medication [2] [21] [26]. 
However, only in 8 to 12 percent of patients treated with high dose corticosteroids for a 
longer period appeared signs of osteonecrosis.  Felson T.  et al. came to the conclusion 
that “The oral dose effect amounts to a 4 to 6 percent increase in the risk of AVN for 
every 10 mg/day rise in oral steroids during the first 6 months of therapy” [7]. Other 
reports cite an elevated risk for AVN at a dose of more than 2 g of steroids within a 
period of about two months [10] [27].  
 
B)  Pathogenesis 
It is still unclear how corticosteroid therapy leads to osteonecrosis. One explanation could 
be a raised intraosseus pressure, which is either caused by a swelling of bone marrow fat 
cells or fat emboli [28]. The increased pressure causes an obstruction of small femoral 
vessels with a following ischemia and death of osteocytes [29] [30]. A possible model for 
increased fat cell content in bone marrow could be that, in vitro, dexamethasone has the 
competence to induce primary marrow stroma cells to differentiate to adipocytes. As 
bone cells and fat cells share a common precursor and dexamethasone can induce 
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adipogenesis, it results in a mismatch between bone and fat cells. This may lead to 
increased intraosseus pressure, venous stasis and decreased arterial perfusion [31].  
However, the negative effects of steroid intake are not only attributable to the 
compromised vascularity, but even more to osteoblasts and osteocytes apoptosis [32] [30] 
[33]. Within the last years it became obvious that apoptosis of osteocytes and lining cells 
leads to interruption in the mechanosensory network of the femoral head and thus to a 
reduced repair mechanism of structural micro damages, followed by collapse of the bone 
[30]. Glucocorticoids have an effect on all bone cells, even on osteoclasts. They decrease 
the production of osteoblasts and osteoclasts, increase the apoptosis of osteoblasts and 
prolong the lifespan of osteoclasts [34].  This process leads to an abnormal bone 
metabolism and thus to reduced bone mass and decreased stability. The thesis of 
osteocytes and osteoblast apoptosis as the major pathogenetic factor in steroid induced 
osteonecrosis is emphasized by the fact that there are not found apoptotic cells in 
osteonecrosis of other etiology,  but only in steroid induced cases [34] [35] [33].  
 
 
 
1.3.2 Alcohol 
 
Studies showed that about one third of patients with idiopathic ONFH have a history of 
regular or excessive alcohol intake [36] [37]. The risk seems to be dose related, but it is, 
nevertheless, difficult to define a harmful quantity. However, it could be seen that an 
intake of more than 400 ml ethanol per week increases the risk of osteonecrosis 9.8 fold 
[2] [25]. Although the exact pathomechanism is still not clear, it seems there is a 
similarity to steroid induced osteonecrosis [25]. Histological surveys on alcohol induced 
ONFH showed an increase of fat cells and marrow fat and thus a reduction of 
osteogenetic cells. In addition to that the increased intraosseus fat content leads to 
elevated intraosseus pressure and thus to venous stasis, diminished blood circulation and 
finally to ischemic necrosis [3]. Besides, there are found elevated serum lipid peroxides, 
which have a pro inflammatory effect and induce degeneration of small blood vessels. 
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This can lead to a reduced bone perfusion, an effect which has also been observed in 
hepatic steatosis [25] [38]. 
 
 
1.3.3 Nicotine 
 
Various surveys showed that smoking is a potential risk factor for osteonecrosis [22]. It is 
assumed that there is an increased risk for common smokers and a cumulative effect of a 
minimum of 20 pack years [10]. Exposition to cigarette smoke does affect every human 
organ system, so it also leads to intramedullary vasoconstriction and in the following to 
an ischemic necrosis of the bone [1]. Nicotine abuse can decrease osteogenesis, bone 
volume and vascular reactivity, which may also explain prolonged healing processes. The 
reduced blood supply and the decline of bone producing and repairing cells lead to a 
vulnerable tissue and an increased risk for necrosis of the femoral head [39] [10]. 
 
 
1.3.4 Physical strain 
 
It seems that hard physical strain does not increase the possibility of ONFH. However, it 
has an impact on the proceeding of a preexisting AVN. This may be the result of physical 
stress induced micro lesions, which can worsen the vascular supply of the necrotic bone 
area [40]. Another reason for strict avoidance of physical strain in patients with 
osteonecrosis is on the one hand a symptomatic improvement of the pain and on the other 
hand a reduced number of insufficiency bone fractures [41]. 
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1.3.5 Genetic  
 
There seem to be various genetic disorders, connected with avascular necrosis in general 
and ONFH in particular. Especially patients with sickle cell anemia are confronted with 
an increased risk of getting ONFH [42]. Approximately about half of patients at the age 
of 35 are affected [43] [2]. These patients suffer from a higher disposition for an 
activation of the coagulation system, which can lead to occlusion of small blood vessels 
and thus to ischemic osteonecrosis [44]. There is also a discussion about other 
coagulation abnormalities, like Factor V Leiden mutation, thrombophilia or 
hypofibrinolysis. They lead to increased incidents of blood clots or to a reduced ability to 
dissolve these clots. It has been shown that up to 82% of patients with ONFH (in contrast 
to 32% in the control group) had at least one coagulation abnormality [10]. Koo, Lee et 
all. found that certain genetic polymorphisms in the endothelial nitric oxide synthase 
(eNOS) gene were frequently present in patients with ONFH. This leads to a reduction of 
vasodilatative effects and an inhibition of platelet aggregation of eNOS and thus to an 
impaired blood supply in the femoral head [39]. A deprived vascularization, as it can be 
found in VEGF-gene polymorphisms, may also be a co-factor for osteonecrosis [45]. Liu, 
Chen et all. succeeded in finding a genetic mutation in three families with autosomal 
dominant inheritance. They detected a genetic disorder in the type II collagene, the major 
structural protein in cartilage [46]. It is hard to decide whether all these genetic disorders 
are risk factors for themselves or they are just acting as co-factors along with other risk 
factors. This would explain why some people with a certain risk exposition get sick, 
whereas others stay healthy. However, the knowledge of the genetic risk is important, 
because it makes it possible to screen people at an early stage. But this is not yet a clinical 
standard. 
Although there are many different risk factors and the exact pathomechanism is still 
unclear, it seems quite likely that a disturbed blood supply, an increased intraosseous 
pressure and abnormal cellular mechanisms lead to impaired nourishment of osseous 
structures and thereby to an aseptic necrosis of the bone [39] [2]. 
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1.4 Clinic  
 
As the clinical course of OFNH is very unspecific and often without any symptoms at the 
beginning, it is difficult to recognize the disease in an early stage, when there would be 
good chances for conservative treatments. The first clinical sign is mostly a deep pain in 
the groin, which may derive from the associated bone marrow edema within the femoral 
head [11] [47]. In this stadium a reduced range of motion, especially internal rotation and 
abduction, of the affected hip is already possible [9]. A clicking sound during movement 
and enormous pain might be a sign for a collapsed femoral head and therefore an 
advanced stage [2].  
 
 
1.5 Radiological Imaging 
 
As the disease starts in most cases with rather unspecific clinical signs, radiological 
imaging is very important in early diagnostics. The first step should always be plain 
radiography, with an anterior-posterior and a frog-leg lateral radiograph [2]. In an early 
stage of the disease there are no specific signs on the x-ray visible, but it is a good tool to 
get an overview about the integrity and the constitution of the hip joint [10]. Radiological 
signs, like cysts, sclerosis, the crescent sign, which derives from subchondral collapsed 
bone, or complete collapse and destruction of the joint, appear on the plain radiograph 
months after the onset of pain [47] [2] [5] [4]. As radiography is a tool for advanced 
stages of ONFH or for the differential diagnosis to arthrotic degenerations of the hip 
joint, the standard for early diagnosis of ONFH is the magnet resonance imaging (MRI) 
[48] [49]. With sensitivity and specificity of 99%, MR imaging is the most accurate way 
for early diagnosis of AVN [2] [5]. A healthy femur shows a high intensity signal, due to 
the hydrogen rich marrow fat. Invasive processes or displace of the fat, like in necrosis, 
lead to an altered signal intensity [4]. The MRI of painful hips often shows a bone 
marrow edema (BME), which appears with low signal intensity in T1-weighted images 
and high signal intensity in the T2-weighted fat suppressed STIR-MRI (Short-Tau 
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Inversion Recovery-MRI) [47] [5]. It is not definitely clear if the BME can be seen as a 
direct precursor of ONFH or just of transient osteoporosis [47] [50]. However, in early 
stages of osteonecrosis there is often a bone marrow edema visible, which can progress to 
a higher stage of ONFH, with subchondral micro-fracture, or disappear completely after a 
certain period of time [5]. Other typical signs of ONFH in MR images, like the double 
line sign or signal intensity changes, hint at the necrotic lesion. A single density line on 
the T1 pictures demarcates the normal-ischemic-bone interface, whereas a double density 
line on T2 weighted images represents the hypervascular granulation tissue, which 
derives from the healthy bone and is a repair mechanism of the necrotic area [2] [51]. 
Another advantage of MRI is the 3-dimensional overview about the whole joint, which 
makes it possible to oversee the exact location and extent of the lesion [51].  
Bone scan or szintigraphy is a previously used nuclear medicine method in osteonecrosis 
diagnostic. Nowadays with high specific MR imaging allowing exact diagnosis of 
ischemic process in the bone, the use of these methods is not state of the art anymore. The 
sensitivity of szintigraphy with technetium-99 is only about 60 % with a false negative 
rate of about 25 to 45% [2] [5]. Mostly in the beginning of the disease these techniques 
are very unspecific, but in the course of the disease they become more sensitive. The 
typical increased uptake as a “cold in hot” pattern can also be seen in infectious processes 
like osteomyelitis or coxitis. With a full-body-scan it is possible to detect multiple 
osteonecrotic lesions [48]. 
Also not within standard diagnostic procedures is the computed tomography (CT), 
although it is a good way to detect a cartilage collapse on an early stage. But its high 
costs and the enormous radiation load make this technique more or less obsolete [2]. 
Other diagnostic tools, like intraosseous pressure measurement, venography or biopsy, 
are not used, because they are very invasive and their sensitivity is not better than MRI 
[2]. 
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1.6 Staging 
 
Osteonecrosis almost always progresses in different stages. These can last 
interindividually very differently and are, until a certain point, at least theoretically totally 
reversible [6]. As stage is the most important factor for prognosis and for the chosen 
treatment, an exact and diagnostically conclusive staging is of great importance [2] [10] 
[3]. The prognosis is highly related to the extent and location of the necrotic lesion. That 
is why almost all staging types include this information, beside different clinical or 
radiological findings [6] [3] [10]. In general, every classification combines clinical signs, 
like pain or reduced range of motion, and radiological pathologies. The most important 
radiographic factors are the integrity of the femoral head, whether the bone is pre- or 
postcollapse. The collapse derives from a mechanical failure of the bone structure. Large 
lesions can be seen by a contour change of the femoral surface or in advanced course by 
femoral head depression, known as the “out of round” appearance. The smaller ones are 
only visible on MRI, by the crescent sign. The larger the collapse, the greater is the risk 
for necessity of total hip replacement. Another prognostic factor is the size of the lesion 
and a possible acetabular involvement. Both are crucial for the kind of treatment and the 
prognosis [10] [9].  
Also of great interest is the location of the lesion. There is a difference whether the 
necrosis is in the weight bearing area or apart from it. In the weight bearing area there is 
greater mechanical strain, what may lead to early collapse of the damaged tissue. Because 
of the importance of correct classification there exist many different types of 
classification.  
One of the elder and currently sometimes used in clinical routine is the staging of Ficat 
and Arlt. They described five different stages, from 0 to IV.  Stage 0 is the preclinical and 
pre-radiological so called “silent hip”, with an increased intramedullar pressure. This 
diagnosis is only possible if there is a confirmed osteonecrosis of the contralateral hip. 
Stage I is only clinical signs, with reduced movement and pain in the groin or the thigh, 
but no radiographic signs. Stage II presents with persistent or increased pain, limited 
range of motion and first radiographic signs, like sclerosis, cysts or diffuse osteopenia. 
Stage III of Ficat and Arlt contains subchondral fracture, with the crescent sign and a 
segmental flattening of the femoral head (“out of round” appearance). The patient suffers 
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from continuing strong pain and limited motion. The loss of articular cartilage, arthritic 
deformation and a diminished range of motion define stage IV [9] [2].  
More commonly used are the classifications of Steinberg (table 1) and of the ARCO 
(association research circulation osseous) (table 2). The Steinberg classification describes 
seven stages plus three stages of extent and grades of involvement of the femoral head, 
whereas the five ARCO stages also take the localization into account. Both classifications 
combine pathopysiological basics and radiologic imaging [6] [5] [52] [47] [48].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage Radiograph signs MRI and bone scan 
Extent or grade of 
involvement 
0 Normal or non diagnostic 
Normal or non 
diagnostic 
Not visible 
I Normal 
Abnormal, changes of 
marrow or bone cells 
A: mild <15% 
B: moderate 15-30% 
C: severe >30% 
II 
Abnormal, cystic and 
sclerotic changes 
Sclerotic changes, 
repair mechanism 
A: mild <15% 
B: moderate 15-30% 
C: severe >30% 
III 
Crescent sign due to 
subchondral collapse 
Subchondral micro 
fractures, crescent sign 
A: mild <15% 
B: moderate 15-30% 
C: severe >30% 
IV 
Flattening of articular 
surface 
Depression of femoral 
head surface 
Flattening of articular 
surface 
Depression of femoral 
head surface 
A: mild <15%,   < 2 mm 
B: moderate 15-30%,  2-
4 mm 
C: severe >30%, >4 mm 
V 
Joint narrowing, with or 
without acetabular 
involvement 
Joint narrowing, with 
or without acetabular 
involvement 
A: mild <15%,    < 2 mm 
B: moderate 15-30%,  2-
4 mm 
C: severe >30%, >4 mm 
VI 
Advanced degeneration, 
osteoarthritic deformation 
Advanced 
degeneration, 
osteoartritic 
deformation 
 
Table 1:  Steinberg classification [44] 
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    Table 1: ARCO classification [5] [6] 
 
The ARCO classification is the most common one in clinical routine. In addition to the 
extent of the lesion, which is described in stages I to III as shown in the table above, there 
can be indicated a localization  for the stages II and III: A: medial, B: central and C: 
lateral. This may be of importance, because grad C has the worst prognosis of these three. 
Although there are five stages (0-IV) in the traditional ARCO classification, there are 
only four stages (I-IV) in clinical use, because stage 0 is neither clinically nor 
radiologically visible, but only histologically [5] [6].  
Due to numerous different staging systems, without a standard unified classification, and 
a lack of inter observer reliability, it is very difficult to compare different studies or 
clinical courses [2] [53].  
Stage Radiograph signs MRI and Bone scan Extent or grade of 
involvement 
0 
(Initial stage) 
Negative Negative Not visible 
I 
(Early Reversible) 
Negative 
Bone marrow edema, 
diffuse subchondral 
changes 
A: < 15% 
B: 15-30% 
C: >30% 
II 
(Early irreversible) 
Sclerosis, osteopenia, 
unspecific 
Necrotic lesion, reactive 
interface “double line 
sign”, “cold in hot” 
A: < 15% 
B: 15-30% 
C: >30% 
III 
(transition stage) 
Subchondral collaps 
“crescent sign”, 
flattening of femoral 
head surface, sclerosis 
Subchondral fractures 
“crescent sign”, “cold in 
hot” 
A: < 15%, < 2mm 
flattening 
B: 15-30%, 2-4mm 
flattening 
C: >30%, > 4mm 
flattening 
IV 
(final stage) 
Complete joint 
destruction, Arthritic 
signs, joint space 
narrowing 
Joint destruction, arthritic 
changes, loss of articular 
cartilage, “cold in hot” 
 
15 
 
It is also possible to perform an exact histological staging, as described by Arlet and 
Durroux in 1973 [9]. But as it is necessary to get tissue by invasive procedure and as the 
histological findings are not consistent with clinic or radiology, it is not performed 
anymore. 
 
As another radiological staging parameter the combined necrotic angle of Kerboul has to 
be mentioned. Although it´s use in clinical routine declined, it is a quite meaningful tool 
to assess the extent and the prognosis of a necrotic lesion of the femoral head. The 
combined necrotic angle of Kerboul is determined by adding the necrotic angles in the 
anterior-posterior and the axial plane of the plain radiograph. First of all the centre of the 
femoral head has to be defined. Thereafter a sector, which describes the necrotic lesion 
on the femoral surface, is measured in both projections (see figure 1 below).  
The two angles are added. [54] [55] 
 
 
 
 
 
 
 
A Kerboul angle <200 degrees counts as a small lesion with a rather good prognosis. 
Angles >200 degrees showed a significant worse outcome after joint preserving therapy 
[56]. 
  
           
 
Figure 1: Schematic depiction of the determination of the Kerboul angle 
[54] 
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1.7 Therapy 
 
As most patients are quite young and naturally the course of untreated osteonecrosis leads 
to the collapse of the femoral head, joint preserving therapy is necessary. There are many 
different treatment options; however, none could proof uniformly successful [57].  
 
 
 
1.7.1 Nonoperative therapy 
 
Table 3 below shows a small excerpt of the literature dealing with conservative treatment 
opportunities for femoral head necrosis. There is a large amount of studies, most of them 
about pharmaceutical therapies. The most commonly used drug in clinical routine is the 
stable prostacyclin analogue Iloprost. There are also some reports about other 
conservative methods, but not that many. A limitation of most works is the small patient 
numbers and the rather short follow up times. Figure 2 shows a chronological timeline of 
the mentioned literature. 
 
Year 
 
Author Journal Title 
 
2005 
 
Aigner et al. 
 
 
Wiener Klinische Wochenschrift 
Bone marrow edema syndrome of the femoral 
head: Treatment with the prostacyclin analogue 
iloprost An MRI-controlled study 
 
2005 
 
Disch et al. 
 
Journal of Bone and Joint 
Surgery 
The management of necrosis-associated and 
idiopathic bone-marrow edema of the proximal 
femur by intravenous iloprost 
 
2005 
 
Wang et al. 
 
Journal of Bone and Joint 
Surgery 
Treatment for Osteonecrosis of Femoral Head: 
Comparison of Extracorporeal Shock Waves with 
Core Decompression and Bone Grafting 
 
2005 
 
Meizer et al. 
 
Wiener Klinische Wochenschrift 
MRI-controlled analysis of 104 patients with 
painful bone marrow edema in different joint 
localizations treated with the prostacyclin analogue 
iloprost 
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2006 
 
Mont et al. 
 
Journal of Bone and Joint 
Surgery 
 
Nontraumatic osteonecrosis of the femoral head: 
Ten years later 
2011 Jäger et al. International Orthopaedics Efficiency of iloprost treatment for osseous 
malperfusion 
2011 Rajpura et al. Hip International Medical management of osteonecrosis of the hip: 
A review 
2012 Beckmann et al. Rheumatology International 
Infusion, core decompression, or infusion 
following core decompression in the treatment of 
bone edema syndrome and early avascular 
osteonecrosis of the femoral head 
2015 Roth et al. Zeitschrift für Orthopädie und 
Unfallchirurgie 
S3-Leitlinie. Teil 2: Atraumatische 
Femurkopfnekrose des Erwachsenen – 
unbehandelter Verlauf und konservative 
Behandlung 
  Table 3: Literature for conservative treatment options 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Literature non operative therapies: Iloprost, Extracorporeal Shockwave Therapy (ESWT) and 
Hyperbaric Oxygen Treatment (HBO) 
 
If the disease is diagnosed in an early stage, it is possible to try conservative methods. It 
is described in literature that early detected small lesions have a chance to recover 
spontaneously [10]. Because of that it is often recommended to reduce weight bearing of 
the affected hip by using a cane or crutches [58]. This may slow down the progression of 
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the disease or lead to a normalization of clinical and radiological findings. It is supposed 
that the collapse of the joint can be caused by trauma related epiphyseal trabecular 
impaction or by an insufficiency bone fracture [41]. The weight bearing reduction can be 
supported by analgesic or anti-inflammatory medication and physical therapy [11]. 
However, this may be very long lasting or even only delay the collapse of the femoral 
head. It has been shown that non weight bearing has a clinical success rate of 22.7%, 
whereas core decompression has a success rate of about 53% [3]. However, the outcome 
can be improved by the avoidance of risk factors, as discussed before. A lifestyle 
modification can also help to save the hip joint. This means a reduction of alcohol 
consumption and a stop of cigarette smoking, as well as a moderate physical training 
without shock load to the affected hip [8].  
 
 
 
1.7.1.1 Drugs 
There are several medicaments in use for treatment of osteonecrosis. The most common 
is the stable prostacyclin analogue Iloprost. It is approved for therapy of critical ischemia 
secondary to peripheral arteriosclerosis, diabetic angiopathy or pulmonary hypertension 
[5] [11] [59]. It causes arterial and venous dilatation, reduces capillary permeability and 
reduces platelet aggregation. Besides the rheological effects on the terminal vascular bed, 
it has also the ability to reduce the concentration of oxygen radicals and leukotriens [58]. 
These effects improve microcirculation and so diminish the edema and thereby 
intraosseous pressure [12]. Administration of Iloprost is only helpful in very early stages, 
like bone marrow edema and ARCO I or II stages [23] [60]. When administered in these 
stages, it leads to a fast improvement of clinical symptoms and a significant pain 
reduction [61] [12]. The drug is given intravenously for five days, with a patient adapted 
increasing dosage [59]. However, there are several side effects of Iloprost. During 
infusion it may come to headache, nausea, flush or cardiac effects, like arrhythmia. A 
therapy with Iloprost is contraindicated during pregnancy, for patients with warfarin or 
heparin anticoagulation and for patients with peptic ulcers or with cardiological illness 
[58] [5] [62]. To improve success rate it is also possible to combine the operative core 
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decompression with an Iloprost infusion. Both treatments alone show similar success 
rates, in combination there are less non responders and a higher success rate [11].   
Other medicaments used for therapy of osteonecrosis are statins, which are mainly used 
in steroid induced ONFH or bisphosphonates, like Alendronate [59] [63]. 
Bisphosphonates have an antireabsorptive effect, by inhibiting osteoclast activity. Thus it 
leads to an increased bone density and may prevent subchondral collapse, in order to 
avoid surgical intervention [64]. Several studies showed that the short term results for 
Alendronate are mainly in ARCO I or II stages with small lesions quite promising. Pain 
as well as functionality improved significantly during a therapy with 10 mg Alendronate 
per day in combination with calcium and vitamin D [64]. In the long term results it could 
be seen that bisphosphonates given in pre-collapse stages can delay bone collapse up to 
4.2 years [23] [59]. Nevertheless, there are some serious side effects, like mucosal 
irritation of the upper gastro-intestinal-system, osteonecrosis of the jaw bone or atypical 
femur fractures, which have to be taken into consideration [64].     
 
 
1.7.1.2 Other conservative measures 
There exist some other, less popular nonoperative treatment ideas, like hyperbaric oxygen 
treatment (HBO) or extracorporeal shockwaves [10]. The hyperbaric oxygen is meant to 
reverse ischemia, by increasing the oxygen concentration in the tissue [59]. Although 
there is a pain reduction in the beginning, it has been shown that it cannot prevent 
subchondral collapse [23].  
Extracorporeal shockwave therapy (ESWT) is a controversial discussed treatment option 
for early ARCO stages or in combination with other joint preserving therapies. It is meant 
to support neovascularization and regenerative, anti-inflammatory processes [65]. 
According to current data, ESWT is not able to delay the collapse of the femoral head 
[23].   
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1.7.2 Operative therapy 
 
In the following tables 4 and 5 and in figure 3 there is given a short chronological 
overview of the literature about operative treatment of osteonecrosis of the femoral head.   
Year Author Journal Title 
1955 Koo et al. Journal of Bone and Joint 
Surgery 
Preventing collapse in early osteonecrosis of the 
femoral head- A randomised clinical trial of core 
decompression 
1985 Ficat et al. Journal of Bone and Joint 
Surgery 
Idiopathic Bone Necrosis of the Femoral Head 
1994 Adrian et al. Journal of Bone and Joint 
Surgery 
Long term results of core decompression for 
ischemic osteonecrosis of the femoral head 
2005 Aigner et al. Wiener Klinische 
Wochenschrift 
Bone marrow edema syndrome of the femoral 
head: Treatment with the prostacyclin analogue 
iloprost An MRI-controlled study 
2006 Mont et al. Journal of Bone and Joint 
Surgery 
Nontraumatic osteonecrosis of the femoral head: 
Ten years later 
2010 Lee et al. Chang Gung Medical Journal Non-traumatic Osteonecrosis of the Femoral 
Head – From Clinical to Bench 
 
2014 
 
Li et al. 
International Journal of 
Clinical and Experimental 
Pathology 
Comparison of bone marrow mesenchymal stem 
cells and core decompression in treatment of 
osteonecrosis of the femoral head: a meta-
analysis 
  Table 4: Literature Core decompression 
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Year Author Journal Title 
 
2001 
 
Steinberg et al. 
Clinical Orthopaedics and 
Related Research 
Core decompression with bone grafting for 
osteonecrosis of the femoral head 
 
 
2010 
 
 
Fang et al. 
 
Chinese Journal of reparative 
and reconstructive Surgery 
Treatment of osteonecrosis of femoral head by 
core decompression combining with autologous 
cortical sustaining bone and cancellous bone 
graft 
 
 
2013 
 
 
Kang et al. 
 
Yonsei Medical Journal 
Clinical results of auto-iliac cancellous bone 
grafts combined with implantation of autologous 
bone marrow cells for osteonecrosis of the 
femoral head: a minimum 5-year follow-up 
 
2015 
 
Shah et al. 
Journal of Clinical 
Orthopaedics and Trauma 
Analysis of outcome of avascular necrosis of 
femoral head treated by core decompression and 
bone grafting 
   Table 5: Literature Cancellous Bone Grafting 
 
 
 
 
 Figure 3: Literature operative therapies 
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1.7.2.1   Core decompression 
Core decompression is the most common operative hip preserving therapy at the time 
[57] [66] [58]. The primary aim of this intervention is a reduction of intraosseous 
pressure, which is meant to be the main pathological factor of osteonecrosis. With a 
decreased intramedullary pressure, there is a chance for normal blood circulation and so 
even revascularization is possible. This may lead, at least in theory, to bone remodeling 
and restitution of the necrosis [11] [5] [67]. The reduced hypertension in the bone 
explains why most patients have a significant pain reduction after the operation [68] [69] 
[70].  Nevertheless, there are many different success rates described in literature. When 
Ficat first brought up this method, he found an overall clinical success rate of 89.5%. He 
also showed that outcome is very much dependent on the stage of the necrosis, as he 
came up with success rates of 93.9% for stage I and 82.5% for stage II. The radiographic 
results, however, were not that positive. Here could have been shown an improvement 
rate of 78.9% [9]. Later studies show a wide range of success rates. It is settled 
somewhere between 63.5% and 84%, but only in early stages of the disease [66] [13] [3] 
[10]. In most cases the clinical symptoms of patients can be improved, although 
radiographic progression of the necrosis is visible. Only in very early stages the disease is 
reversible. But the earlier core decompression is performed, the better are the long term 
results for the patients. Size and location of the affected area are also important risk 
factors for the outcome of core decompression [66] [13] [67].  
The procedure of core decompression is quite easy. The patient is in general or spinal 
anesthesia and the location of the necrotic area is detected with C-arm imaging. Then 
surgery is performed by a lateral approach. A guide pin is drilled from the proximal 
lateral femur, about 4 cm below the trochanteric ridge, into the lesion. When aiming is 
confirmed by C-arm image, a core reamer is drilled over the guide pin and creates a 10 
mm bone channel. After that the necrotic bone can be removed [57] [13]. This way of 
performing the core decompression brings the risk of subsequent collapse of the femoral 
head, as well as an increased danger of proximal femur fracture, in case of weakening the 
cortical wall of the femoral neck. A complication rate of about 4% to 10% has been 
described.  
Thus there is also the possibility to perform a multiple drilling with small pins in a fan-
shaped way. There seems to be no significant difference in success rates, but the multiple 
drilling shows less complications, like subtrochanteric fractures or hip joint penetration 
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[67] [8]. However, it is a disadvantage that there can´t be taken histological samples and 
it is not possible to perform cancellous bone grafting. 
As it is crucial to penetrate the necrotic area, there is also the possibility to perform core 
decompression with a navigation system. It showed that the precision of the drilling could 
be improved and the radiation time was shorter than in conventional procedure [71] [72].  
For the performance there has to be a virtual connection of the fluoroscopic images and 
the position of the surgical instruments. This makes it necessary to attach markers to the 
surgical instruments, the patient and the C-arm. Therefore, a reference array with passive 
reflecting marker spheres is attached to the surface of the patient and the instruments. 
Visualization of the necrotic area has to be done by the C-arm fluoroscope, which is 
connected to the navigation system. After that no further intraoperative images are 
needed. A standard drill is equipped with a marker-clamp and measured with a special 
calibration tool in order to inform the navigation system about the length, diameter and 
position of the tip of the instrument. After the surgical instrument is visualized on the 
touch-screen monitor, the drill is placed into the bone by continuous online control of the 
navigation system. Virtual connection of the position of all the reference markers enables 
the orientation of the drilling guide in two fluoroscopic planes simultaneously. This may 
lead to a significant reduction in the distance to the target when compared with 
conventional core decompression (0.4 mm in the navigation group versus 0.88 mm in the 
conventional group). Another benefit can be seen in the reduced radiation time. There is 
an obvious difference between navigated core decompression and the traditional 
procedure. It has been shown that the radiation exposition can be reduced for the patients 
and the staff from 3.1 seconds to less than one second   [71] [72]. 
Postoperatively partial weight-bearing is recommended for six to eight weeks. During the 
first period of full weight-bearing, high impact activities should be avoided for about one 
year. Physiotherapy should be performed to strengthen the muscles and to regain range of 
motion [14].      
Core decompression can also be combined with autologous bone grafting. There exist 
different kinds of grafts. The first possibility is to transfer vascularized or 
nonvascularized bone grafts, like a part of the fibula or the tibia. The main goal of these 
transplants is to strengthen the femoral head, in order to avoid a collapse or a fracture 
[73] [57] [17]. It is also possible to transfer cancellous bone from the iliac crest, greater 
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trochanter or proximal femur into the bone channel. It is suggested that the cancellous 
bone contains osteoprogenitor cells, which may improve healing and structural recovery 
of the necrotic lesion [74] [8]. A comparable method is the implantation of bone marrow 
mesenchymal stem cells. These cells have been suggested to promote osteogenesis and 
angiogenesis, which leads to a reduction of symptoms in the short term, but also to a 
shortening of the disease and a partial recovery of the necrotic area [66].  
Although core decompression has been performed for about three decades, its effect on 
the progression of osteonecrosis is still not clear. There are some hints that combined 
methods, like bone grafts and mesenchymal stem cell implantation might bring better 
results than core decompression alone. It has to be considered that core decompression is 
helpful particularly in early stages [57] [66] [3] [75].   
 
 
1.7.2.2  Proximal femoral osteotomy 
Whereas core decompression can only be performed in early stages and before collapse 
of the hip joint occurs, osteotomy can also be helpful in early post-collapse stages [8] [2]. 
The main goal of osteotomy is to transfer the necrotic bone area out of the major weight 
bearing area. This leads to a relief of the necrotic or collapsed lesion and thus to a 
reduction of pain and a delay of progress. Another positive side effect of the operation 
might be a reduction of intraosseous venous pressure and thereby an improved 
vascularity as described before [67] [17]. There are mainly two types of osteotomy: the 
trans-trochanteric rotational osteotomy and the intertrochanteric varus or valgus 
osteotomy [8] [10]. The trans-trochanteric rotational osteotomy allows a large degree of 
translation of the necrotic area; however, the intertrochanteric osteotomies are less 
technically demanding [2]. Criteria for the performance of an osteotomy are an age under 
45, an early postcollapse or late precollapse stage, no joint space narrowing or acetabular 
involvement, a small to medium lesion and no history of high dose steroid intake [2]. 
Success rates vary a lot in literature. It might be somewhere between 60% to 93% long 
term hip survival rate [67] [2]. Although the results seem to be quite good, osteotomies 
are seldom performed and not well accepted by patients. This may derive from its great 
invasivity, its technical complexity or the potential risk of morbidity. Common problems 
are a nonunion of the bones and there are reports that a total hip replacement after failed 
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osteotomy is often connected with difficulties or complications [8] [2] [67]. The ongoing 
improvement of arthroscopy may help surgeons to visualize and quantify cartilage 
damage and so lead to better long term results [8].           
 
       
1.7.2.3  Total hip arthroplasty 
When the disease progresses, joint preventing therapy is almost impossible. In these cases 
total hip arthroplasty may be the only solution left. It is an effective and viable option for 
patients with an extensive postcollapse lesion, with secondary osteoarthritis or acetabular 
involvement [67] [2]. Total hip replacement leads to significant pain reduction and good 
functional outcome [2]. However, there are some concerns for this treatment. As mostly 
younger patients are affected, there is a high possibility for revision arthroplasty. There 
are also some reports about polyethylene wear and osteolysis leading to aseptic loosening 
of total hip replacement after ONFH. This was mentioned in about 8% to 31% of cases 
after ONFH. In recent times, survivorship of implants increased due to new materials, 
like ceramic bearing or porous materials [67]. Even several risk factors may affect the 
duration of total hip replacement after osteonecrosis, like steroid intake, alcohol abuse, 
systemic lupus erythematodes or organ transplantation [2] [1]. The decision for cemented 
or cementless total hip arthroplasty has to be done by clinical issues. The cemented 
implant may have a higher loosening rate, whereas the cementless implant showed 
periprosthetic osteolysis [1]. There are reports that patients with ONFH prior to total hip 
replacement have a decreased bone mineral density in comparison to patients with THR 
due to degenerative processes. This effect was visible in the acetabular region as well as 
around the femoral system. This may be an explanation for high loosening rates among 
patients with total hip replacement after AVN [76] [77].   
An alternative to total hip replacement might be limited femoral resurfacing arthroplasty. 
It is mostly an option for large lesions with late stages, but without acetabular 
involvement. The benefit is that femoral head and neck bone stock are preserved, which 
means that revision to total hip arthroplasty is not complicated thereby [19] [2]. In the 
meantime it is seldom performed because studies showed high failure rates up to 31% 
[67].  
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2.        Question 
 
As there are many different therapy concepts and no common consent about the 
effectiveness of each, it is of great importance for the mostly young patients to get facts 
about the clinical outcome of the different treatments. It is also inevitable to test and to 
introduce new methods of therapy concepts and of quality management.  
In the light of the above this study is built up of three different questions.  
The first part is a retrospective trial to show the effectiveness of common head 
preserving therapy concepts of ONFH. The goal is to judge the different treatments 
according to patients’ subjective feelings and to the clinical outcome. For that patients 
were split up according to the therapy they had. The first group included only patients 
treated with core decompression. Patients in the second group were treated with core 
decompression in combination with autologous cancellous bone grafting. In order to get 
comparable results, only patients with an ARCO II avascular necrosis of the femur head 
were taken into account. Each therapy group was operated by one surgeon. Surgeon 1 
always performed the core decompression, surgeon 2 made the cancellous bone graftings. 
Both collectives were matched according to sex and age.   
The second part deals with new technical methods to measure the precision of core 
decompression. By virtual three dimensional reconstruction and measurement of the 
necrosis and the drill hole it shall be given an impression to coming possibilities in 
modern medicine. It has to be discussed whether conventional core decompression by C-
arm imaging is really exact enough to get into the center or at least, into the area of the 
necrotic bone. Furthermore it shall be assessed if there is a difference in precision 
between the drilling with the small pins and the trephine.  
The third part deals with bone marrow perfusion measuring. This is a quite new topic, 
as there exists only very little literature about bone marrow perfusion measuring. There 
are some reports that there is a connection between reduced bone mineral density (BMD) 
and an impaired bone marrow perfusion in patients with osteoporosis. Another field of 
application may be the differentiation between benign and malign changes within the 
bone marrow [78] [79]. As this technology is not established in clinical routine so far, we 
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tried to make a descriptive work about a possible application in femoral head necrosis as 
a basis for future analysis.   
 
3.         Material and Methods 
 
3.1 Patients 
 
 
Figure 4: Overall patient collective in the period from 2006 to 2012 
In figure 4 above the overall patient collective is shown. There were all patients included, 
who had a treatment for a diagnosed osteonecrosis of the femoral head at the Department 
of Orthopedic Surgery, University of Regensburg, during the time from 2006 to 2012. In 
this time there were 289 hips with a diagnosed avascular necrosis. 145 of these hips were 
primarily provided with a THR, because the stage was already progressed or it was the 
patients` wish. 110 affected hips were tried to treat with joint preserving therapies like 
core decompression, autologous cancellous bone grafting, Ilomedin infusions or 
combination of core decompression or cancellous bone grafting with Ilomedin infusion. 
48 femoral heads aggravated despite of the therapy, so they had to undergo total hip 
replacement. The other 62 femoral heads showed no aggravation which would have made 
a prosthetic treatment necessary. This group represents the main patient collective, 
observed in this survey.    
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For the survey only the patients who did not need THR were taken into account. So there 
were 57 patients with 62 treated hips, who met our inclusion criteria. These 44 men and 
13 women were contacted written and by phone call. There was no answer from 20 
persons. Three patients did not want to come to the hospital for examination, because 
their hip was good so far. Two patients denied participation without a statement, one 
denied due to current problems with his treated hip. In one case the patient had to 
undergo THR in the mean time and one patient had passed away. A total of 28 patients 
with 32 treated hips had to be excluded (overview see figure 5).  
 
 
 
 
In general, 29 patients with 31 treated hips were left for this study (see table 6 below). 
Nine (31.03%) female and 20 (68.97%) male patients, with a mean age of 43 years (SD 
10.15, range 22-61) when being treated could be included in this study.  
There was 14 times the left hip affected and 17 times the right one. Bilateral involvement 
was prevalent in two male patients.  
Body mass index (BMI) ranged between 21.2 kg/m
2
 to 33.8 kg/m
2
 with a mean BMI of 
27.09 kg/m
2 
and a SD of 2.79 kg/m
2
.   
    Figure 5: Consort Diagram: Joint preserving therapy 
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Patients were categorized according to the ARCO classification [80]. Stadium I was 
found five times, stadium II 23 times and stadium III three times.  
No systematic disease, like sickle cell anemia, Gaucher's disease, Caisson disease or 
autoimmune diseases (systemic lupus erythematosus, Sjögren's syndrome or scleroderma) 
were reported in this group. One patient had a hip injury.  One patient had a 
hyperuricemia and one patient a hyperlipidemia. Five patients reported subjective alcohol 
abuse and five patients reported subjective nicotine abuse. Eight patients had a history of 
corticosteroid intake.  
Four patients were treated with an Ilomedin infusion therapy and 14 hips with core 
decompression (CD) with K-wire in a fan shaped fashion. Of these 14 joints, seven cases 
were additionally treated with an Ilomedin infusion. On 14 femoral heads core 
decompression (CD) with autologous cancellous bone grafting of the iliac crest was 
performed. Three of them had an additional Ilomedin infusion.  
          Mono 
        therapy 
           Double 
           therapy 
 Triple            
therapy 
 
Therapy-
Group 
1 2 3 4 5 
CD Ilo CD + CBG CD + Ilo CD + CBG + 
Ilo 
male (n) / 
female (n) 
4/2 4/0 8/3 5/2 1/2 
mean 
age(years); 
min/max; 
SD 
44.5; 
30/54;     
9.4 
52.0;      
41/57;         
6.6 
40.9;      
22/54;      
10.0 
40.4;     
28/54;        
8.7 
45.3;     
30/61;      
12.7 
mean BMI 
(kg/m
2 
) 
min/max; 
SD 
27.7; 
27.5/29.3; 
3.7 
26.8; 
25.3/27.7;   
4.4 
27.3; 
24.3/33.8;  
1.6 
26.9; 
21.2/33.5;  
2.4  
25.8; 
25.6/26.3;  
1.4 
ARCO(n): 
I 
II 
III 
1 
5 
0 
3 
1 
0 
0 
10 
1 
1 
6 
0 
0 
1 
2 
        Table 6: Baseline table of treatment groups with number (n) of patient depending on ARCO stage     
    (CD core decompression; CBG: cancellous bone grafting; Ilo: Ilomedin infusion) 
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The mean disease free survival was 4.93 years (59.1 months), with a range from 26.3 to 
92.9 months. 
All patients gave written informed consent to the study.  
As a comparison group we observed the patients who had to undergo THR after a joint 
preserving therapy attempt. There were 46 patients with 48 treated hips. The mean age of 
these subjects was 46 years, with 32 male and 14 female persons. In general there was a 
mean period of 10.6 months, with a range from 1.3 to 67.6 months, between the first joint 
preserving trial and the final prosthetic treatment. Table 7 below shows the baseline 
characteristics of this group with differentiation according to the treatment.  
 
Group CD CD + CBG Ilo 
male (n) / female (n) 15/6 17/6 2/2 
mean age (years); 
min/max; SD 
50.4; 30/72;          
11.0 
42.4; 29/73;   
10.9 
47.5; 22/61;     
15.1 
ARCO (n): 
I 
II 
III 
IV 
 
2 
11 
7 
1 
 
0 
14 
9 
0 
 
0 
2 
2 
0 
Time between first 
joint preserving 
therapy and THR 
(months); min/max; 
SD 
 
9.5; 1.3/26.8;            
7.0 
 
11.3; 3.0/67.6; 
12.9 
 
11.9; 4.9/20.4;    
5.6 
 
Table 7: Baseline characteristics with number (n) of patients with conversion to THR (CD: core          
decompression; CBG: cancellous bone grafting; Ilo: Ilomedin infusion) 
 
The patients with a history of conversion from joint preserving therapy to THR were not 
contacted or clinically examined.  
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3.2 Groups    
 
All patients of the examined collective were split up into groups according to the question 
of the survey. 
 
3.2.1 Comparison between core decompression and cancellous bone 
grafting 
 
For the first part of the study 22 patients met the participation criteria (Table 8). There 
were three inclusion criteria, which led to a rather small number of patients. First of all 
only patients with a diagnosed osteonecrosis in ARCO stage II before treatment were 
taken into account. They were set up into two different groups, according to the previous 
therapy. Half of the patients had a history of core decompression, the others were treated 
with additional cancellous bone grafting. The second criterion was that both populations 
had been operated by the same surgeon each. Surgeon 1 performed the core 
decompressions  of group 1. Surgeon 2 did the cancellous bone graftings after core 
decompression in group 2. As a third condition the cases were matched according to sex 
and age in both groups. By this eleven patients in each group were left. In general there 
were 14 male and eight female persons. The mean age was 41.3 years in group 1, with a 
range from 28 to 54, and 42.0 years in group 2 with range from 22 to 54. In group 1 the 
mean BMI was 26.4 kg/m², with a range from 21.2 to 29.3 kg/m² and a standard deviation 
of 3.2 kg/m². The mean BMI in group 2 was 27.4 kg/m², with a range from 24.3 to 33.8 
kg/m² and a standard deviation of 2.7 kg/m². The mean follow up time of patients with 
core decompression was about 4.0 years (48.0 months), with a range from 26.3 to 68.5 
months. The mean follow up time in patients with cancellous bone grafting after CD was 
about 5.2 years (69.2 months), with a range from 38.0 to 92.9 months.   
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Table 8: Core decompression vs. cancellous bone grafting (CD: core decompression; CBG: cancellous bone 
grafting; Ilo: Ilomedin infusion)    
 
The patients in whom joint preserving therapy had failed were spilt according to the 
respective therapy group. In the core decompression group there were 21 subjects, 23 had 
a history of cancellous bone grafting and four persons had an Ilomedin infusion therapy 
(see table 7 above).   
 
 
3.2.2 Precision measurement of core decompression 
 
In the second population were only patients treated with core decompression. 15 (79%) 
male and four female (21%) patients, treated between the years 2007 and 2013, were 
included in this analysis. Bilateral femoral head necrosis was only prevalent in three men, 
leading to 22 hips available for this study. The overall mean age of the patient collective 
was 41.2 years with a standard deviation (SD) of 9.9 years.  
Body Mass index (BMI) ranged between 21.2 kg/m² and 33.8 kg/m² with a mean BMI of 
27.1 kg/m² and a SD of 3.3 kg/m².  
In unilateral cases about 60% of the cases the right hip was affected, in 40% of the cases 
the left hip was affected. 
Group Group 1: CD Group 2: CD + CBG 
male(n) / female(n) 7/4 7/4 
mean age (years); 
min/max; SD 
42.3;                      
28/54; 8.9 
41.9;                                     
22/61; 10.8 
mean BMI  (kg/m
2
); 
min/max; SD 
 
27.1; 
21.2/33.5; 3.5 
 
27.2; 
24.3/33.8; 2.4 
ARCO stage II (n) 11 11 
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Patients were divided into two groups. Group A only contained patients with core 
decompression alone. Group B represents patients with cancellous bone grafting after 
core decompression as therapy (see Table 9). In group A there are ten cases; in group B 
there are twelve hips after cancellous bone grafting. There was no discrimination between 
ARCO stages.    
 
 
. 
 
 
                         
   
 
 
 
 
 
 
Table 9: Patients for three dimensional precision measuring (CD: core decompression;  
CBG: cancellous bone grafting) 
 
 
 
 
 
 
 
 
 
Group A:  CD B:  CD + CBG 
male (n) / female (n) 7/3 11/1 
mean age (years); 
min/max; 
 SD 
43.1; 
28/54;  
9.3 
40.0; 
22/54;  
10.1 
mean BMI (kg/m²); 
min/max;  
SD 
26.7;  
21.2/33.5;  
3.9 
27.4;  
24.3/33.8;  
10.1 
ARCO (n): 
I 
II 
III 
 
2 
8 
0 
 
0 
9 
3 
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3.2.3      Quantitative measurement of femoral head perfusion 
 
The third group only contains patients who had a special contrast agent MRI. This was 
not possible to perform in every case. One patient already had a contrast agent, so he 
could not be given another dosage. One patient could not be given contrast agent due to 
allergy. One patient had already had a MRI so she did not want to perform another one. 
Of one patient there could not be done MR imaging, due to his claustrophobia. One 
patient denied informed consent to MRI. In general, five patients had to be excluded. 
There remained 24 patients with 26 treated hips in this survey. There was no limitation 
according to ARCO stage or therapy regimen. There were 18 male and eight female 
patients included. Three hips were classified as ARCO I, 20 hips as ARCO II and 3 hips 
were ARCO III. The mean age in this group was 41.1 years. Eleven patients were treated 
with core decompression. Six of them had gotten additional Ilomedin infusion. 
Cancellous bone grafting was performed at twelve hips, one with supplementary 
Ilomedin infusion. Three patients were treated with Ilomedin infusion only. The exact 
distribution of therapy and ARCO stage is shown in table 10 below.    
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 Mono 
therapy 
Double 
therapy 
Triple 
therapy 
Therapy-Group 
1 2 3 4 5 
CD Ilo CD + CBG CD + Ilo CD + CBG 
+ Ilo 
male / female 3/2 0/3 10/1 4/2 1/0 
mean age 
(years); 
min/max; SD 
42.8;    
30/43;       
8.6 
51.7; 
41/57;    
7.5 
40.9; 
22/54;  
10.0 
40.0; 
28/54;  
9.3 
30.0 
mean BMI 
(kg/m²); 
min/max; SD 
28.4; 
27.5/29.3; 
0.7 
26.6; 
25.3/27.7; 
1.0 
27.5; 
24.3/33.8; 
2.6 
25.7; 
21.2/33.5; 
4.7 
26.3 
ARCO (n) 
I 
II 
III 
 
 0 
 5 
 0 
 
2 
1 
0 
 
0 
9 
2 
 
 1 
 5 
 0 
 
0 
0 
1 
Table 10: Patients for perfusion measuring (CD core decompression; CBG: cancellous bone grafting; Ilo: 
Ilomidin infusion) 
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3.3  Clinical protocol and scores 
In the following chapters the different protocols of three subgroups are explained. 
 
3.3.1 Clinical comparison between core decompression and cancellous     
bone grafting 
 
All patients with a successful joint preserving therapy were examined according to the 
same study protocol: physical examination of the hip, including range of motion (ROM), 
pain-level or any contractions of the hip joint. The ROM was calculated as a sum score of 
hip flexion, adduction, abduction, internal and external rotation. This refers to the range 
of motion in the Harris Hip Score, with 300° to 210° being an excellent result, 209° to 
160° a good result, 159° to 100° a moderate result and <100° a poor result [81].  
Followed by clinical standard procedure with radiological imaging, including plain 
radiographs in anterior-posterior projection and as a second plane in Lauenstein 
projection. Thereafter, a MRI was performed. At last patients answered several scores, 
including the Harris Hip Score (HHS), Hip Disability and Osteoarthritis Outcome Score 
(HOOS), EuroQol 5D (EQ-5D), Short Form 36 Questionnaire (SF-36) and pain intensity 
during rest and physical strain with use of the Visual Analogue Scale 10 mm (VAS). 
The evaluation of the radiological images was based on the ARCO classification. 
Therefore the plain radiographs and the MRI images were assessed. So all examined hips 
could be given a current staging.  
The evaluation of the HHS was done on the online platform 
www.orthopaedicscores.com. Therefore patients´ answers were transferred anonymously 
to the website and the score was calculated. 
The appraisal of HOOS was also performed on www.orthopaedicscores.com. Patients 
answers were again transferred anonymously and the program reckoned the final score. 
 EQ-5D analysis was performed according to Hinz A et al. [82], using the recommended 
sum-model. This leads to a possible score between 0-100, with a high sum score 
representing a high life quality. The test assesses the subjective health status according to 
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five different levels: mobility, the ability to look after oneself, activity of daily life, pain 
and fear.   
SF-36 score was evaluated in every single dimension of the test, giving an overview 
about the general life quality.  
 
 
3.3.2 Three dimensional measurement of drilling precision 
 
Of all patients magnetic resonance imaging (MRI), using a Philips Ingenia 1.5 T 
magnetic resonance imaging system with a digital surface coil, of the pelvis and the hip 
was retrieved. The imaging was performed in supine position. MRI slices were saved in 
DICOM format with a slice thickness of three millimeters and 20 slices in each 
weighting. 
3D reconstruction, segmentation and measurements were done using Simpleware Scan IP 
(Simpleware, Exeter, UK).  
The method derives from the susceptibility artifacts in the MRI technology. This means 
that during the drilling micro metal particles of the drill are abraded. Those particles can 
be detected postoperatively by MRI. 
The drill hole and the necrosis areal as the regions of interest (ROI) were marked using 
the provided manual segmentation tools (figure 6). In order to allow 3D reconstruction 
the ROI has to be manually segmented in all three dimensions. Both, necrosis origin and 
drill holes were reconstructed in this manner.  
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Figure 6: Segmentation of the necrotic area 
 
Figure 7: Necrotic area without segmentation 
In figure 6 the necrotic area is colored in red. It has been marked as a ROI with the 
manual segmentation tool. Figure 7 represents the necrosis before the segmentation 
process. This marking of the defect zone has to be repeated in every slice of the MRI in 
which the necrosis is visible. The same has to be done with the drill channel. In figure 6 a 
short part of the drill channel can be seen underneath the necrosis. In this case a core 
decompression with a small pin had been performed.  
By applying an ‘extended marching cube algorithm’3D reconstruction was ultimately 
achieved, from which the measurements were taken. For this the maximum elongation of 
the drill hole and the necrosis areal was measured in millimeters in all three spatial planes 
39 
 
(xyz) as a vector. Of these two vectors (drill hole and necrosis areal) the center point was 
measured. The deviation of the center point of the drill hole to the center point of the 
necrosis areal is a measure of how accurate or precise a drill channel can be placed into 
the femoral head in order to meet the necrotic area. An alignment of both center points is 
desired. If the drill hole was achieved in a fan-shaped fashion, the center point of all three 
tips of the drill holes was determined (as described above) and the deviation from the 
center point of the necrosis was measured. The schematic drawing below (figure 8) 
shows how the distance between the center point of the necrosis and the center point of 
the drill hole is measured.  
 
 
Figure 8: A schematic drawing of the definition of precision 
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Figure 9: Program surface with three dimensional reconstructions 
 
In figure 9 the reconstructed formation is shown in the three dimensional coordinate 
system, before measurements are performed. It shows the surface and the tools of the 
program.  
 
 
Figure 11: Measurement of the necrotic area in the x-
axis 
Figure 10: Measurement of the center point of 
the necrosis 
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Figure 11 shows the measurement of one necrotic area in the x-axis. This procedure had 
to be performed in every axis and the center point had to be found for each (figure 10). 
The same working steps had been performed for the drill channels.   
 
 
3.3.3 Semiquantitative measurement of the hip perfusion 
  
The measuring of the hip perfusion was done by clinical standard with a contrast-agent 
improved T1 weighted sequence (DIXON) in the MRI, using a Philips Ingenia 1.5 T MR. 
Imaging was performed in supine position with a digital surface coil. Dynamic images 
were obtained using a short T 1 weighted gradient echo sequence (mDIXON_W_dyn_tra; 
TE: 1.8/ 3.9 ms; TR: 5.6 ms; flip angle 15°). The contrast agent was Dotarem® 
(Gadoleic-acid) Guerbet-company, with a concentration of 0.2 ml/kg/BW. The 
application was done via high-pressure-injector by Med-Tron-company, with a flow rate 
of 2 ml/sec. The injection was followed by a 20 ml NaCl flush, with a flow rate of 2 
ml/sec. Dynamic MR imaging started with a maximum delay of 17 seconds after contrast 
agent injection.  
 
The examination is composed of four series of axial slices. The first series is performed 
native, without contrast agent. Thereafter follow three sequences at different times after 
the application of the contrast agent. 
At first the reference slice has to be determined, hereby that slice has to be chosen in 
which the femoral head shows the biggest diameter (figure 12). Thereafter follows the 
determination of the signal intensity by a so called ROI-measurement (region of interest). 
Here it is important, that the ROI´s circle occupies the femoral head sub-maximally. The 
cortical bone should not be occupied by the ROI (figure 13). So only the contrast signal 
intensity in the bone marrow is measured.   
Every single one of the four performed measures has to be done with the same sized ROI 
at the identical slice. The first ROI is set in the native slice, so it works as a blank value. 
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The following three series are performed at defined times after the injection of the 
contrast agent. They are taken at different stages of distribution in the bone marrow 
(figure 14). In the figures 13 and 14 there are shown two measurements of the same 
patient at different times after the contrast agent injection. According to the distribution 
of the agent the signal intensity is not identical in both. It can be seen that the ROIs are 
always set in the identical place and the same slice (represented by the “table position”).  
In theory the relation of the signal increase in the ROI after the contrast agent has been 
administered shows the amount of perfusion in the femoral head and allows a comparison 
between different patients or may enable to draw conclusions about certain pathologies.  
 
 
 
 
 
 
 
 
 
 
Figure 12: Determination of the slice in which the femoral head shows the maximum diameter 
(TP: table position) 
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Figure 13: Performance of ROI-measurement (A: area; U: perimeter; d: diameter;  
avg: average signal intensity; sd: standard deviation; max: maximum signal intensity;  
min: minimum signal intensity; TP: table position) 
 
 
 
Figure 14: ROI-measurement in following distribution phase. (A: area; U: perimeter;  
d: diameter; avg: average signal intensity; sd: standard deviation; max: maximum signal intensity;  
min: minimum signal intensity; TP: table position) 
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3.4 Statistics  
 
Statistical analysis for the comparison between the two groups was carried out using the t 
test for the clinical test results and the earlier described scores. In these cases when 
normality testing failed and t-test could not be used, the Mann–Whitney Rank Sum Test 
was applied. All analyses were performed using SigmaPlot 11.0 (Systat Software Inc., 
Chicago, IL, USA). Statistical comparisons were made at a 0.05 level of significance.  
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4 Results 
 
4.1.1 Clinical comparison of core decompression and cancellous bone    
grafting 
 
With the performed check up examination we wanted to see if core decompression or 
cancellous bone grafting is superior to the other.  
At first we wanted to know if patients suffered pain in their treated hips. For that they 
were asked to mark their pain level on a scale from 0 to 10, meaning from no pain at all 
to the worst even imaginable pain (according to the VAS). The patients were asked to do 
the marking one time for the pain level during rest and the second time during hard 
physical strain. A medium pain (VAS 5) during rest was given only by one patient in 
group 1 (core decompression). In group 2 (cancellous bone grafting) there were two 
patients with very mild pain (VAS 1) and one case with medium strong pain (VAS 5) 
during rest. For the pain level during strong physical strain patients with core 
decompression stated a medium pain level of 3.3 with a range from 0 to 8. The medium 
activity pain in the cancellous bone grafting group was 2.2 with a range from 0 to 7. 
There could be shown no significant difference between the two therapies (Figure 15).   
 
Figure 15: Box plot VAS during physical strain 
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In the clinical examination the range of motion of the treated  hip was tested and 
documented in degrees. The test scores in every movement axis (flexion, adduction, 
abduction, internal and external rotation) were added up to a total Range of Motion score. 
In group 1 there was a mean range of motion of 224.5° with a range from 190° to 265°. 
The mean score in group 2 was at 232.9°, ranging from 140° to 280°. T test showed 
p=0.225 and therefore no significant difference between the two groups (figure 16). 
 
Figure 16: Box plot range of motion 
 
 
All patients were asked to answer several questionnaires about their general well being 
and the state of the operated hip. The comparison of the two therapy groups revealed no 
statistical significant difference in any of the scores. In the hip specific “Harris Hip 
Score” and “Hip disability and Osteoarthritis Outcome Score” the bone grafting group 
showed slightly better results, however they were not statistically significant (see table 11 
and figure 17 and 18). Patients with core decompression achieved better results in the SF 
36 score, but again without any significance.  
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Score CD CD + CBG 
 
Harris Hip Score 
mean value (range, p) 
 
87.7 
(58-100, 0.362) 
 
93.2 
(58-100, 0.362) 
 
HOOS 
mean value (range, p) 
 
75.6 
(37.2-95, 0.470) 
 
81.2 
(37.2-100, 0.470) 
 
EQ-5D 
mean value (range, p) 
 
79.1 
(50-100, 0.788) 
 
80.9 
(60-100, 0.788) 
 
SF 36 physical health 
mean value (range, p) 
 
46.6 
(21.2-56.2, 0.599) 
 
42.3 
(20.1-57.3, 0.599) 
 
SF 36 mental health 
mean value (range, p) 
 
53.2 
(37.8-59.6, 1.000) 
 
49.8 
(32.9-61.3, 1.000) 
               Table 11: Evaluation clinical scores (CD: core decompression; CBG: cancellous bone grafting) 
 
 
 
Figure 17: Box plot Harris Hip Score                                Figure 18: Box plot HOOS 
 
As a further evaluation every treated hip was staged according to the ARCO 
classification, using plane radiographs and MRI. In group 1 there were two hips with an 
ARCO stadium I, five times stage II and four times stage IV. Leading to a calculated 
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mean ARCO stage of 2.5. In group 2 there were six hips with a stage II and five cases 
with stage III, also leading to a mean stage of 2.5 (Figure 19). 
 
 
Figure 19: Distribution of ARCO stages after femoral head preserving therapy (number of cases) 
 
As both groups only contained patients, who were treated in an ARCO II stage, it shows 
that in general 13 hips (59.1%) did not progress in the disease. Two of them (9.1%) even 
improved after the therapy. Six subjects (54.5%) of the cancellous bone grafting group 
stayed in their initial pre-therapy ARCO stage II. In the core decompression population 
this could be seen for five patients (45.5%). Two hips (18.2%) of the core decompression 
group could be diagnosed an improvement to ARCO stage I in the follow up. For the 
overall group, nine femur heads aggravated to a higher ARCO stage.  Five hips of the 
cancellous bone grafting group (45.5%) showed a worsening to ARCO III. Four treated 
hip joints (36.6%) of the CD group deteriorated to ARCO IV with total radiological 
destruction of the femoral head.     
For the evaluation of the conversion cohort (patients who had to get a THR after the 
initial joint preserving therapy attempt) the different therapy groups were compared 
according to the time until therapy failure, which was marked by the necessity of THR. 
There was an overall of 48 patients with a mean time of 10.6 months from joint 
preserving therapy attempt to prosthetic supply. The core decompression group had a 
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mean success period of 9.5 months (1.3 to 26.8 months, SD 7.0 months). Those treated 
with CD and cancellous bone grafting showed a mean term of 11.3 months (3.0 to 67.6 
months, SD 12.9 months). Statistical analysis of the time period brought forward no 
significant difference between the two different groups (p=0.54). The four patients treated 
with Ilomedin infusion came to a mean success time of 11.9 months showing again no 
statistical relevant benefit in comparison to the two interventions with CD vs. Ilo - (p=0.54) 
and CBG vs. Ilo (p=0.90).    
 
 
 
4.2         Three dimensional measurement of drilling precision   
 
After the three dimensional model had been created from the performed MRI, the center 
points of the necrosis and of the drill hole had to be determined in every of the three 
coordinate axis. Afterwards the distance between the two center points was measured in 
millimeters. The values of the distances in every single axis were summed up to a total 
distance. The volume of the necrosis is given in milliliters (ml). The mean volume of the 
necrotic area in group A was 7.79 ml ranging from 1.74 ml to 23.68 ml, with a standard 
deviation of 7.7 ml. The mean necrotic volume in group B was 21.1 ml, with a range 
from 6.0 ml to 46.2 ml and a standard deviation of 12.4 ml. The added mean distances in 
group A had a mean of 3.58 mm, ranging from 0 mm to 14.06 mm with an SD of 4.2 mm. 
The mean distance sum in group B was 3.91 mm, with a range from 0 mm to 15.27 mm 
and a SD of 4.7 mm (see also table 12).  
Group Core decompression (A) Cancellous bone grafting (B) 
Necrosis (ml) 
min/max, SD 
7.79                                
1.74/23.7, 7.7 
21.1                                     
6.0/46.2, 12.4 
Distance (mm) 
min/max, SD 
3.58   
 0.0/14.06, 4.2 
3.91                                  
0.0/15.27, 4.7 
      Table 12: Baseline values of necrosis and deviation (Distance: the mean values of the distances in every 
single axis were summed up to a mean total distance) 
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The evaluation showed in both groups that the necrotic area had been reached by the 
drilling in all cases. It did not matter how large the necrotic bone area had been. The 
drilling pin (group A) or the reamer (group B) had at least reached into the defect zone at 
all times.  
The second question was if there is a difference in precision between the drilling with the 
small pin (core decompression) or the 10 mm trephine (cancellous bone grafting). 
Statistical analysis showed that there cannot be found a significant difference in the 
precision (p=0.459) (see figure 20 and table 13).  
 
     Figure 20: Box plot precision 
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 CD CD + CBG 
Mean necrosis in X-axis 
(mm) min/max, SD 
21.5                            
6.7/40.7; 9.3 
32.34                             
19.7/45.8; 7.5 
Mean necrosis in Y-axis 
(mm) min/max, SD 
11.01                           
6.6/16.0; 3.7 
19.15                               
11.5/35.4; 6.4 
Mean necrosis in Z-axis 
(mm) min/max, SD 
26.95                         
13.1/42.0; 11.1 
30.86                            
17.2/42.2; 7.4 
Mean volume of necrosis 
(ml) min/max, SD 
7.79                            
1.74/23.7; 7.7 
21.1                                 
6.0/46.2; 12.4 
Deviation distance in X-axis 
(mm) min/max, SD 
4.95                             
0.0/12.0; 3.4 
4.63                               
0.0/11.2; 3.9 
Deviation distance in Y-axis 
(mm) min/max, SD 
1.02                               
0.0/10.2; 3.1 
0.0                                         
0.0/0.0; 0.0 
Deviation distance in Z-axis 
(mm) min/max, SD 
4.77                                 
0.0/14.1; 4.8 
7.13                                    
0.0/15.3; 4.9 
        Table 12: Values of precision measuring (CD: core decompression, CBG: cancellous bone grafting) 
   
 
         
 
Figure 21: MRI with three dimensional reconstruction of the necrosis and the drill holes 
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Figure 21 shows a three dimensional MRI excerpt of a patient with bilateral femoral head 
necrosis. On the left side the necrotic area had been drilled with a reamer and cancellous 
bone grafting. On the right side the necrosis had been drilled with several small pins. The 
necrosis and the drill holes had been reconstructed as described above (pp. 37-40). It is 
obvious that in both cases the necrotic area has been hit by the drilling.  
 
 
 
 
 
 
 
 
 
 
 
 
           Figure 22: Patient with cancellous bone grafting 
In figure 22 the necrosis had been treated with cancellous bone grafting. In the right 
femoral head the necrotic area and the course of the drill hole are reconstructed. The 
necrosis is in the lateral segment of the femoral head. It can be seen that the surgeon had 
hit the defect zone with the trephine. The necrosis is measured in every axis, as an 
example the extent in the z-axis is shown in figure 23.   
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Figure 23: Measurement of necrosis in z-axis 
 
 
4.3          Semiquantitative measurement of bone marrow perfusion 
 
For this part the images, which had been created by dynamic MR sequences had to be 
measured, as described on the pages (41 to 43). First of all the sick hips that had been 
treated with any of the joint preserving therapies, core decompression, cancellous bone 
grafting, Ilomedin infusion or combination of them, were evaluated. The non affected 
hips were evaluated as well, given there was no THR. For the evaluation the signal 
increase of the perfusion was calculated. At first there was taken a baseline signal 
intensity, before the administration of the contrast agent. Thereafter the mean value of the 
signal intensity of the following three arterial sequences was calculated. With this the 
percentage signal intensity increase from the baseline intensity without contrast agent to 
the mean arterial signal intensity with contrast agent was received. All 26 treated hips had 
a mean signal intensity increase of 26.4%, with a SD of 26.3% and a range from -3.9% to 
116.9%. 
 When split into the different therapy groups (see graphic in figure 24 below), the patients 
with a combined therapy of core decompression and Ilomedin injection showed the 
highest increase of the signal intensity (44.41%, SD 28.25%, range from 5.94% to 
116.93%). They were followed by the patients with core decompression and cancellous 
bone grafting (27.62% intensity increase, SD 23.9%, range from 5.59% to 96.48%). The 
subjects treated with core decompression alone showed a signal intensity rise of 12.42%, 
54 
 
standard deviation 11.9% and a range from -3.86% to 31.15%. The group treated with an 
Ilomedin infusion alone showed a signal intensity increase of 15.31%, SD 9.9%, ranging 
from 2.93% to 27.22%. The smallest increase was found in the one patient treated with 
cancellous bone grafting in combination with Ilomedin injection (8.25% increase).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Figure 24: Box plot signal intensity increase in different treatment groups      
          (CD: core decompression; Ilo: Iloprost infusion; CBG: cancellous bone grafting)  
 
There were 14 untreated hips. They showed a mean signal intensity increase of 29.42%, 
with a SD of 27.6% and a range from 4.4% to 114.8%. The box plot below (Figure 25) 
shows a comparison between the signal intensity increase in the hips, which had a joint 
preserving treatment of the ONFH, and the contra lateral healthy hip without necrosis and 
treatment.  
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                 Figure 25: Signal intensity increase treated and healthy hips 
It showed that there is no statistical relevant difference between the healthy and the 
treated hips (p=0.86). The split up of the untreated hips shows that patients who had a 
therapy with the blood flow stimulating Iloprost, have a mean signal intensity increase of 
41.4%, whereas patients without a pharmacological therapy had a mean signal increase of 
22.7%.   
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5          Discussion  
5.1          Comparison of core decompression and cancellous bone grafting 
 
Osteonecrosis of the femoral head is a wide spread disease, which is mostly common 
among young adults. As these patients are mainly in their best years it is not only 
physically disabling, but it also generates great economic costs. The concerned people 
often suffer for a long time until they get the right diagnosis. Ohzono et al. found a mean 
time between the onset of the first symptoms and the initial diagnosis of about eight 
months, with a range from one month to eight years [83]. The constant pain and the loss 
of mobility mean an enormous reduction in quality of life. These young patients have 
great demands on therapy.  
This makes it necessary to compare the two most common joint preserving procedures, 
core decompression and cancellous bone grafting, to clarify which shows better clinical 
outcome.  
Of course it has to be discussed if there are possibilities to prevent the prevalence of 
ONFH, by avoiding certain risk factors. It is commonly known that smoking and alcohol 
abuse are very important impact factors on the prevalence of aseptic necrosis [25] [2] 
[10].  
Besides of lifestyle modifications there are also iatrogenic factors, which can influence 
the risk for aseptic necrosis of any location. Steroids, for example, are very important and 
powerful drugs in modern medicine. Their use is widely spread, e. g. in transplantation 
medicine or as immunosuppressives for chronic inflammatory diseases. Physicians 
should be aware that these medicaments may lead to harmful side effects. It has been 
shown that a daily dosage of more than 20 mg or a cumulative dose of more than 3 g of 
prednisolon or its equivalent increase the risk of osteonecrosis [2]. Often these drugs are 
given for too long or in too high dosage. Mont et al. stated that a dosage of more than 2 g 
for more than two to three months or a cumulative dose of about 5928 mg prednisolon or 
its equivalent increases the risk for osteonecrosis significantly [10].  
However, there are no general figures about the percentual distribution of cases of ONFH 
to the mentioned risk factors, but it is stated that about 41% of AVN are due to 
corticosteroids and about 19% are due to alcohol abuse [70]. Many of the patients show 
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no history of any of these mentioned risk factors but are related idiopathically. This 
means it is of greatest importance to have efficient therapeutic options.  
Although total joint replacement made revolutionary progress during the last few years, it 
is no good alternative for younger patients. It turned out that the younger the patients are 
undergoing THR, the worse is the outcome, regarding clinical and subjective results [84]. 
The lifetime of the prosthesis is significantly shorter than in elder patients. It could be 
demonstrated that patients undergoing total hip replacement due to osteonecrosis have a 
reduced bone mineral density [76]. This may lead to premature loosening of the implants 
[76] [77]. It showed that the etiology of the avascular necrosis has an important influence 
on the results of hip arthroplasty. It seems that steroid induced necrosis is connected with 
the highest loosening rates, whereas patients with necrosis after immunosuppressive 
medication or alcohol abuse suffer higher rates of infections [85].  
Younger patients are more active and therefore the strain on the implant materials is 
higher. This could lead to more aseptic loosening or primary implant failures [86]. The 
loosening of the materials necessitates repeating surgeries, which have an increased risk 
of perioperative complications, like bone fractures or infections. But even without 
extreme physical strain, the implants do not last longer than 10-20 years in average [70]. 
This means the patients have to undergo two or more revision procedures, which can 
cause operative difficulties. These problems make it necessary to have reliable joint 
preserving alternatives, which may at least delay the necessity of total hip replacement.  
Besides of conservative methods, mentioned at the beginning, core decompression or 
cancellous bone grafting are the two most common therapeutic options first described by 
Ficat and Arlt [9]. These two operative methods are both only for early stages [13] [70]. 
However, they can be more helpful in further progressed stages than the conservative 
alternatives. Core decompression is known as a therapy concept for about 60 years [9] 
[14]. The pathophysiological findings of Ficat and Arlt showed that it is necessary to 
reduce intraosseous pressure and thereby relief the pain and stop the bone destruction [9]. 
Another operative therapy is cancellous bone grafting, which is derived from the same 
pathogenetic approach to reduce intramedullary pressure. In addition to the 
decompression aspect some authors described that bringing new cancellous bone into the 
defect area, makes the healing more efficient [73] [74]. The vital bone material is meant 
to start an intraosseous healing process. It is the conception that the cancellous material 
contains osteogenitor cells [66] [20]. This surgical technique is widely spread in 
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orthopedic procedures, e. g. when it is necessary to reconstruct small bone lesions in the 
acetabulum during total hip replacement. Although the mentioned aspects seem to make 
cancellous bone grafting superior to plain core decompression, there are certain aspects 
against it [17]. At first the operative effort is larger for cancellous bone grafting. By core 
decompression the drilling is only performed with thin pins, causing only a small cortical 
defect. The trephine, which is necessary for bone grafting, removes a bigger part of the 
lateral cortical bone by insertion. This may cause a structural instability and in 
consequence a fracture of the collum femoris if a partial load bearing is not complied. 
Another aspect is the harvest of the cancellous bone. Normally the cancellous bone 
grafting is performed as a “reversing graft” [74]. This means that the healthy cancellous 
bone cylinder which lies lateral of the necrosis is removed and filled into the drill channel 
[16] [15]. However, it showed that there are more potent osteogenetic stem cells in the 
spongiosa of the iliac crest [87] [88]. So the graft could be taken from there, with 
disadvantage to a second wound. The iliac crest is very well supplied with blood; in rare 
cases this may lead to severe bleeding and blood loss. Nevertheless the procedure is well 
established, documented and common in orthopedic surgery [15] [16].  
There is no consent in literature if one therapy is superior to the other, as there are no 
sufficient stage-related comparisons so far [88] [69].   
We saw the necessity to make a comparison between the two procedures. In literature 
there are almost no comparative studies. Most trials deal with core decompression as a 
joint preserving therapy [13] [71] [11] [14] [69].  
Our results show that there are no significant differences between core decompression 
and cancellous bone grafting in clinical outcome. Most patients in both groups mentioned 
only mild pain in rest or during physical strain (VAS 3.3 in CD group and VAS 2.2 in 
bone grafting group (CBG)) with a medium time of 48 months after the therapy in the CD 
population and about 69.2 months in the CBG group. This means that both interventions 
can ease the pain. To our knowledge there are no comparable long term pain data (up to 
almost five years after the initial therapy) in literature available. So we provide data about 
good long term pain reduction for CD and CBG after femoral head necrosis.  
Besides of the pain, mobility is of greatest importance for the patients. The extent of 
movement in every direction was added up as a complete range of motion (ROM) sum. 
We found only a small difference between the two groups. The cancellous bone grafting 
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subjects showed slightly better results, 224.5° (range from 190° to 265°, SD 24.96) for 
CD vs. 232.9° (range from 140° to 280°, SD 34.0) for CBG. In none of the functional or 
lifestyle scores there was a statistical significant difference between the two groups. To 
our knowledge this is one of the first times that the range of motion has been tested after 
such a long period of time in such a detailed way. In the most reports in literature about 
the follow up after therapy of AVN there is only the general description of “clinical 
improvement” [11] [74] [73]. This is mostly meant as a combination of reduced pain and 
an improvement in everyday mobility of the hip joint.  
Further we performed a retrospective evaluation of the operated hip from clinical 
standard radiographs. As all included hips were originally staged as ARCO II it is 
noticeable, that in the bone grafting group there were only “no progression” (ARCO stage 
II) or a “mild progression” to ARCO III. Whereas in the core decompression group there 
could be found a progression even to stage ARCO IV. Also in a small amount of cases 
there was a mild improvement to stage ARCO I. Most cases remained at stage ARCO II. 
This indicates that the core decompression alone could have a greater progression rate 
than the bone grafting. However, this is only radiologically and is neither represented in 
the clinical outcome, nor is it statistically significant.  
Last we also performed an evaluation of some clinical scores. Among them were hip 
specific ones, like the Harris Hip Score and the HOOS, as well as general health scores, 
like the SF-36 score and the EQ-5D.  
The analysis showed that patients with cancellous bone grafting had slightly better results 
in the hip specific scores (Harris Hip Score: CD 87.7, with range from 58 to 100, SD 
13.79 versus CBG 93.2, range from 58 to 100, SD 16.19; HOOS: CD 75.6 range 37.2 to 
95, SD 17.71 versus CBG 81.2, range from 37.2 to 100, SD 19.95). But these results were 
again not statistically significant.  
These results are remarkable because of the very long follow up time of about four years 
in the CD group and even more than five years in the CBG cohort. When compared to 
data in literature the maximum follow up periods are 12 months. In comparison to these 
rather short period follow up our patient collective shows very good results regarding to 
the hip specific scores. In literature 12 months follow up results for the Harris Hip Score 
of 72.25 to 88.42 are reported [73] [11] [11] [73]. These are encouraging figures for a 
good long term success after a joint preserving therapy.  
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In contrast to that the patients with a “normal” core decompression had equal or slightly 
better results in the general health scores (EQ-5D: CD 79.1, range from 50 to 100, SD 
16.25 versus CBG 80.9, range from 60 to 100, SD 16.24; SF-36 physical health: CD 46.6, 
range from 21.2 to 56.2, SD 9.74 versus CBG 42.3, range from 20.1 to 57.3, SD 12.32; 
SF-36 mental health: CD 53.2, range from 37.8 to 59.6, SD 5.79 versus CBG 49.8, range 
from 32.9 to 61.3, SD 12.88).  
Compared to figures mentioned in literature the SF-36 results are a bit worse in our 
population. The mean mental health SF-36 in literature is at about 63.63 to more than 
87.53. The physical health aspect of the SF-36 is reported with about 42.77 to 83.13 [11]. 
It is hard to understand why there is such a discrepancy between the excellent hip specific 
results and the self assessment of the general health. This might be due to the long time 
which patients are tainted with the illness.  
As a summary it can be stated that both interventions are equal according to the clinical 
outcome and the subjective perception of the patients. The most important difference 
between the two procedures is that the cancellous bone grafting is more surgical 
demanding than core decompression. But when it is performed by an experienced 
surgeon, there seem to be no increased complication rates. In conclusion it could be 
stated that more extensive necrotic areas should be treated with core decompression with 
or without a combined cancellous bone grafting. Smaller lesions should be treated with 
the less invasive drill or K-wire than a trephine.  
This work faces several limitations: first is the rather limited number of subjects. There 
were only 22 hips included with 11 patients in each of the two groups. But the 
strongpoint of this part of the study is that we considered only ARCO II stages, in order 
to avoid a selection bias between the ARCO stages and performed a matching according 
to age and sex. Earlier publications showed a survivorship for stage II necrosis after core 
decompression of about 80% for three years of follow up [63].   
The above mentioned reasons made it necessary to exclude several patients and led to a 
reduced number of subjects for our comparison. A further strength is that we matched in 
this retrospective survey the follow up times for both groups in the range from 26.3 
months to 68.5 months in the core decompression group and from 38.0 months to 92.9 
months in the cancellous bone grafting group. At last it would be desirable to have a 
comparison of the baseline clinical scores and pain levels. Surely a prospective study 
would be the golden standard. 
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 The power of this trial comes from the high level of homogeneity of the two observed 
groups. The matching according to ARCO stage, sex, age and time after surgery in follow 
up may equalize any specific differences between male and female patients in each age 
group. Furthermore, we decided to make a limitation on ARCO II stages. This quite early 
stage is normally the most common stage when patients are diagnosed first. Earlier 
publications showed that stage II is the most promising early advanced stage of the 
disease for joint preserving therapies [60] [14] [63]. Another advantage was that only 
patients treated by two surgeons were taken into account. By this we minimized the inter-
individual differences of the surgical skills. These limitations led to a smaller number of 
subjects, but also to a high grade of comparability. Besides, the long follow up time of the 
patients is remarkable. We met the patients on average of 4.6 years after their therapy. 
This shows that both interventions enable patients a good quality of life, by low pain 
levels and an almost normal mobility. Also no further progression was seen with a 
possibly necessity of arthroplasty supply. 
However we have to remind that there were patients with a stage II lesion who had to 
undergo hip arthroplasty after a joint preserving therapy attempt. There were 11 hips with 
a stage two necrosis that needed THR after a mean period of 9.5 months after core 
decompression. In the CBG collective there were 14 stage II hips with a failure of the 
joint preserving attempt after a mean time of 11.3 months. In general it can be seen that 
50% of the hips treated with core decompression showed a long term survivorship.  
 In the cancellous bone grafting group the long term survivorship is at 44%. These results 
are a little bit worse than those reported in literature, but this may be due to the very long 
follow up time  in our subjects  [63] [10].  
Another interesting aspect that can be observed is that failure of joint preserving therapies 
occurs rather early (within one year in our survey). After a progress free time of more 
than one year, deterioration of the treated hip seems to be more unlikely.  
As described above we also took a look at all subjects who did not benefit from the joint 
preserving therapy. They had to undergo total hip replacement after the failed therapy 
attempt. However it is not possible to assess how fast this natural destructive course will 
proceed in the forefront [23]. It is of great importance to delay a necessary prosthetic 
treatment as long as possible, to save the mostly young patients from repetitive prosthetic 
surgeries, which are in many cases connected with increased peri-operative risks [76]. 
For that reason we asked if there was a difference of the time period from the first joint 
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preserving therapy attempt until the performance of THR between the different therapy 
concepts.  
In general there were 48 patients with a mean delay of prosthetic therapy of 10.6 months. 
The longest time between the joint preserving therapy and the necessity of a final 
prosthetic treatment could be seen in the four patients only treated with Ilomedin 
infusion. It was possible to win almost one year (11.9 months) before joint replacement 
was necessary. This group was followed by core decompression with cancellous bone 
grafting(CBG) with 11.3 months. The shortest success period was seen for patients after 
core decompression (CD) with 9.5 months until the joint replacement. But due to our 
small numbers there was no statistical significance to call one therapy concept superior to 
the others. The relatively good results of Ilomedin infusion mono-therapy may be due to 
the small patient number, which means that only selected patients with early stages and 
mild symptoms have been offered this therapy option. The difference of the progressive 
free time between the core decompression group and the cancellous bone grafting group 
is too small as it could be given a recommendation for one of them. Altogether it is not 
clear why the joint preserving therapies did not work in these patients, in comparison to 
our main patient collective. Maybe there were certain risk factors or secondary illnesses 
which had an influence on the therapy. As this survey is a retrospective trial and the 
patients with conversion to total hip replacement were not re-examined, it is not possible 
to answer these questions satisfyingly. In order to clarify the risk factors for a therapy 
failure it is necessary to perform further prospective studies to get more information 
about the course of the disease and to make it possible to decide which therapy concept 
fits best for every patient individually.              
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5.2         Three dimensional measuring of drilling precision 
 
For the success of core decompression or cancellous bone grafting it is vital that the 
necrotic area is hit by the drilling instrument [13]. Only when the sclerotic rim around the 
necrosis is broken, the intraosseous pressure can be relieved. Although the operative 
procedure is not easy to perform in some cases, it is of great importance to hit the 
necrotic zone, in order to stop the progress of the disease [71] [69].  
Moreover there is also the risk of complications, like infection or fractures [66]. In the 
traditional way of core decompression the intraoperative navigation is performed with 
plain 2-dimensional C-arm imaging. This may sometimes be difficult, because the 
necrosis is hard to detect on the images and imaging has to be done in different planes to 
verify the location of the drilling pins [13]. In the last few years intraoperative navigation 
systems spread and became an alternative operation feature. The technology should help 
to increase precision of the intervention and to minimize the radiation time [72].  
The most important aspect in core decompression seems to be the reduced number of 
drilling corrections. The directional changes of the pin lead to multiple drilling, which 
can weaken the femoral neck. This seems to be especially significant for obese patients, 
because the spatial orientation is more difficult here [71]. Different authors suggest to hit 
the central part of the necrotic area [71] [72]. Up to now it is not clear if a decentral hit of 
the necrotic area is also successful because it had not been analyzed yet.  
It can be discussed if it is really necessary that the drilling does exactly hit the central 
point of the necrosis. It seems reasonable that core decompression can also work when 
the pin hits a decentral part of the necrotic area. It is only crucial that the sclerotic rim 
distal to the necrotic area is broken up, so intraosseous pressure can be relieved and blood 
supply can be restored inside the defect zone [9].   
In our trial we analyzed if the necrosis was hit by the drilling in every treated subject. As 
a second question we tried to figure out if there is a difference in precision between core 
decompression with small pins and one single drilling with a 10 mm trephine as in 
cancellous bone grafting?  
We observed 22 patients with a treatment history of either core decompression or 
cancellous bone grafting. Ten hips were treated with core decompression, while the other 
twelve had a cancellous bone grafting therapy. For this analysis there were no limitations, 
except for a MRI, which could be used for the three dimensional segmentation.  
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The segmentation and the three dimensional reconstruction of the necrosis and the drill 
channel showed that in every case the necrosis was hit by the drilling. This means the 
precondition for a successful intraosseous pressure relieve was given in every observed 
hip. We found no difference concerning the area or the volume of the necrosis. The 
necrotic area in the core decompression group had a mean volume of 7.79 ml ranging 
from 1.74 ml to 23.68 ml. The mean necrotic volume in the bone grafting group was 21.1 
ml, with a range from 6.0 ml to 46.2 ml. A possible explanation for the evident volume-
difference between core decompression and core decompression with cancellous bone 
grafting might be the operation procedure. Whereas for core decompression only little 
drills are hit into the bone and the necrosis, the cancellous bone grafting is connected 
with a far larger intrusion into the bone architecture. Some authors suggest that the 
necrotic material has to be removed, leading to a cavity surrounded by healthy bone. Into 
the resulting hole the healthy cancellous graft has to be inserted [16] [15]. This leads to 
remodeling processes in the former necrotic area and its surrounding, which let´s the 
necrosis look larger on the MRI.   
 
For the first part of the analysis we looked if the drill channel or the cancellous graft was 
within the necrotic volume.  This can be seen on MR images, but the spatial position is 
only identifiable in the three dimensional reconstruction. Figure 26 shows the necrosis 
and the drill channel in the MRI. On the left side a part of the necrosis and the channel 
with the cancellous bone grafting is visible. At the right side a small part of the necrotic 
lesion and faintly the drilling channel are recognizable.    
 
Figure 26: MRI with bilateral ONFH and cancellous bone grafting 
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Figure 27 shows the three dimensional reconstruction of the necrosis and the cancellous 
bone grafting. The necrosis and the channel, which is necessary for the bone grafting, are 
reconstructed. In both cases the necrosis is hit by the drilling. 
 
 
 
 
 
 
 
 
     Figure 27: Three dimensional reconstruction of necrosis and bone grafting 
            
 
 
 
 
 
 
 
        
 
 
 
 
 
Figure 28: Reconstruction of multiple drilling 
CD 
 
Figure 29: Reconstruction of multiple drilling 
CD medial view 
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In the figures 28 and 29 the three dimensional reconstruction of a multiple drilling core 
decompression is shown. Figure 30 represents the underlying MRI image of the 
reconstructed K-wire drilling. The necrosis and the multiple drillings are recognizable. It 
can be seen that the necrotic area has been hit by the drilling several times. The K-wire 
got into the defect zone in the peripheral part as well as into the central part. This allows a 
good decompression effect and may induce the formation of new blood vessels. This 
“microfracturing-effect” may lead to osteogenesis [13]. Nevertheless, a problem of this 
way of core decompression is the weakening of the cortical bone. As it can be seen in the 
figures above, the surgeon did not perform the drilling in a fan-shaped way, but with 
several parallel drillings. Thereby the corticalis had to be penetrated more often. This 
may lead to an increased risk of insufficiency fractures. However, we have not seen this 
complication with K-wire technique so far because of partial load bearing 
postoperatively.  
 
The second question dealing with three dimensional reconstruction and precision 
measuring was, if there would be any difference in precision between core decompression 
and cancellous bone grafting. The surgical procedure on the femoral head is basically 
similar for both. The main difference is that for our bone grafting cases there are used ten 
millimeter trephines, whereas for core decompression alone only small pins are 
necessary. The spatial orientation is in both interventions provided by multi-plane 
radiographic imaging.  
Figure 30: MRI of necrosis and multiple 
K-wire drilling 
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For this precisions comparison we set up two groups, group A: core decompression (CD), 
group B: cancellous bone grafting (CBG).    
The first group consisted of ten patients, seven male and three female subjects, with 
ARCO I or II stages.  
In the second group were eleven male and one female patient, with ARCO stage II or III.  
After the segmentation and three dimensional reconstructions of the necrotic areas and 
the drillings, the measuring had been performed as described before (pp.37 to 40).  
The results showed that there is no difference in drilling-precision between the two 
methods. This may lead to the conclusion that the intra- and post-operative risks of a 
bigger drill channel, as performed for cancellous bone grafting, could be avoided by 
using only small K-wire pins or a smaller drill. However, one of the main benefits of 
cancellous bone grafting is the transfer of healthy spongiosa into the necrotic lesion. This 
aspect is not regarded in this part of the survey.  
The mean deviation of the K-wire from the center point of the necrosis in the CD group 
was 3.58 mm. The mean distance between the central point of the necrosis and the middle 
of the trephine in the bone grafting group was 3.91mm. This difference was not of 
statistical significance (p=0.459). This means that although for cancellous bone grafting a 
bigger drilling instrument is used, there is no significant difference in precision. The 
rather big deviation of the drilling from the necrosis center point results from the addition 
of all deviations in every spatial axis to one sum score.  
The results of this trial show that the established joint preserving operations, core 
decompression and cancellous bone grafting, are very precise methods, when performed 
by experienced surgeons. In our opinion the result of core decompression does only 
depend on the fact if the necrotic area has been hit or not. It seems that there is no 
necessity to get exactly into the center point. This means it has to be discussed if it is 
really necessary to install expensive navigation systems, when our results show that all 
conventionally performed interventions got successfully into the defect zone. Aspects in 
favor would be a reduction of radiation dose and time for the patients and the surgeons, 
shorter operation times and easier orientation in obese patients [71]. However, it is 
necessary to perform further studies in order to answer this question definitely.  
This trial shows the comparison of drilling precision for core decompression and 
cancellous bone grafting. Even more interesting is the use of the modern technology of 
three dimensional segmentation and reconstruction. This new tool may be established in 
the future and could be an enormous help for operation planning and performance. In the 
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special case of ONFH it allows the surgeon an exact spatial imagination of the location 
and the shape of the necrosis. This may lead to even higher success rates of joint 
preserving therapies, as the perfect drilling position and direction can be planed pre-
operatively. At the moment the manual segmentation is rather elaborate, but with further 
development the process could be automated.  
To our knowledge this is the first study which uses this kind of technology to evaluate the 
precision of core decompression.   
Apart from that we have to state that at least midterm results are the same for core 
decompression and cancellous bone grafting. But in order to get more valid information 
about the advantages of either of the techniques more work has to be done. At first 
studies with longer follow up times are necessary to show long term success rates.  
A second topic would be the assessment of the quality of bone healing and mineralization 
in each treatment group. Is it better in bone grafting cases compared to core 
decompression, as we would it expect to be? To answer this question a prospective follow 
up with regular pre- and postoperative bone density measuring would be necessary. 
At last we tried to find out if there might be a connection between the size of the necrotic 
lesion and the progress of the disease. Therefore we compared the ARCO stage of the 
necrosis before and after the therapy in combination with the lesion´s size. In literature 
the size of the necrotic area is seen as a possible risk factor for a destructive progress. 
This is represented in the Kerboul angle or in the sub-classifications A to C which can be 
added to the ARCO stages [89, 54, 90, 5, 6]. In our trial we do not have the angle or the 
percentage share of the necrosis on the femoral head, but we have the volume. So we 
tried to figure out quantitatively if there might be a trend recognizable that a greater 
volume leads to progress and thus to a higher ARCO stage.  
In the core decompression group there were five patients with a necrotic volume smaller 
than 3 ml (1.74 ml to 2.98 ml). None of them showed a progress in the ARCO staging 
after the intervention. They all were stage II or better. Three subjects showed an 
improvement, two stayed stable. The other five patients of the core decompression group 
had a necrotic volume of more than 3 ml (4.71 ml to 23.68 ml). Four had a progressive 
course, leading to an ARCO IV stage at the follow-up examination.  
In the cancellous bone grafting group we found six patients with a necrosis smaller than 
20 ml (6.0 ml to 17.3 ml). Five of them did not progress in ARCO classification (four 
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times Stage II, one stage III). Only one hip showed a progress from stage II to III. The 
other six subjects had a necrotic volume of more than 20 ml (22.3 ml to 46.2 ml). Here 
we observed an aggravation to a higher stage in three cases, a stable course in two 
patients and an improvement in one hip. The higher volumes in the CBG group can be 
explained by the intervention itself and the MRI technique. A bigger trephine is used, so 
there is a larger lesion and the susceptibility artifacts that are shown by MRI are thereby 
bigger. 
The described findings match pretty much the common opinion about the correlation 
between the size of the necrotic area and the risk of a progressive and destructive course 
published by Kaushik und Stöve [8] [54]. Although our number of cases is too small to 
make a statistically significant statement, we take this as a confirmation that it is of great 
importance for the outcome of the treatment procedure to be performed at an early 
moment, when the defect zone is still small. Therefore an early and expedient application 
of diagnostic steps has to be performed. The current golden standard for early diagnosis 
of osteonecrosis is the MRI. However, there might be possibilities in the future to 
recognize a disturbed perfusion of the femoral head on the very beginning.  
In the following chapter a method is discussed which may be able to provide the 
possibility to detect the earliest signs of a beginning impairment of the intraosseous blood 
flow.          
 
 
 
5.3         Quantitative measuring of femoral head perfusion  
 
This part of the work is based on several publications about the use of dynamic contrast 
enhanced MRI perfusion measuring of the bone marrow for different diseases of the bone 
[91] [78]. In this study we took a look at 23 patients with 26 treated hips with a mean of 
55 months after therapy. There was no limitation to treatment, ARCO stage or time after 
therapy.  
Several surveys showed that there is a correlation between MRI perfusion signal and 
microcirculation [92] [93] [78].  However, there are many factors, which can influence 
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the MRI signal intensity.  Biffar and Bauer were able to proof that perfusion decreases 
with age and bone marrow fat content. Bauer was able to demonstrate a significant 
decrease in signal intensity with increasing age in a study with 30 persons with a 
homogeneous malignant bone marrow infiltration and  94 healthy persons [79] [91].   
It has been tried to establish the technique as a diagnostic medium for different bone and 
soft tissue processes. In musculoskeletal tumors MRI is an acknowledged diagnostic 
measure. Biffar showed that semiquantitative perfusion measuring could be helpful to 
differentiate between benign and malignant processes although a clear correlation 
between increased perfusion and malignant processes could not be found [93].  
Another very important field of application is osteoporosis.  It had been shown that a 
decrease in perfusion measuring is related to a reduced bone mineral density (BMD), 
which is the pathogenetic correlate of osteoporosis [92] [94]. However, it is not finally 
clear if the decreased perfusion and the increased osteoporosis risk are due to a reduced 
blood supply of the bone marrow or due to an increase of bone marrow fat [93] [95].  
Another question is, if there is a difference to those patients who had a joint preserving 
therapy. It has to be asked if there is a correlation between bone marrow perfusion and a 
process of healing within the bone marrow structure. 
In our survey we were able to get the necessary data, as there was made a MR imaging of 
every patient in the clinical postoperative routine. We found that the method works and 
can be performed quite easily.  
However, we have some limitations: First it is still quite difficult to evaluate the raised 
data, as we do not have sufficient comparison groups or data, due to lack of subjects in 
our study, as well as due to missing data in literature.  
In their basic work on this topic Saifuddin et all. found that there is a wide range of signal 
intensity increase in healthy individuals (4.4% to 55.7%) [96]. This makes it quite 
difficult to compare different treatment groups or even untreated patients with each other. 
 In order to see if there is a difference in perfusion of the femoral head in patients who 
have a history of avascular necrosis, it is necessary to establish a control group of 
subjects with healthy hips. It is questionable if in our patient collective can be found a 
significant disorder of the perfusion, as everyone of them had a successful joint 
preserving therapy. As the pathogenesis of femoral head necrosis is meant to be of 
vascular genesis, the therapy should have improved the microcirculation impairment. As 
a conclusion this would mean that the improved circulation, represented by physiological 
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perfusion figures, lead to healing processes within the affected bone marrow area [10] 
[63].   
This may lead to the assumption that there should not be found a difference in perfusion 
between this collective and a control group. However, this is only a theoretical approach. 
In our study this is supported by the fact that there is no significant difference between 
the patients´ treated hips and the unaffected contralateral hips (mean signal increase 
26.4% versus 29.4%, p=0.86).   
The plainest increase in the healthy hip group was found in patients with core 
decompression in combination with Iloprost infusion (mean signal increase of about 
84.6%). The most noticeable fact is that in general there can be observed a serious 
intensity difference in this group between patients who had a pharmacological therapy 
with Iloprost to stimulate the blood flow, in comparison to those who had no such 
infusion. The mean signal intensity increase in the subjects with an infusion therapy was 
41.4% versus a 22.7% increase in patients without drug infusion in the follow up. It is 
possible that the signal intensity increase is due to an improved circulation, as a result of 
the vaso-active agent.  
These results are consistent with reports that Iloprost has a long term healing effect on 
peripheral circulation in patients with therapy resistant peripheral ulcers [97]. So we 
could assume that this effect is comparable in avascular necrosis.  
 In our population we saw a significant better perfusion even 2 to 7 years postoperatively. 
Although the Iloprost infusion therapy is currently still an off label therapy, the data 
above give strong hints for a long term effect on blood flow improvement. Nevertheless 
there are further studies necessary to prove the impact of the joint preserving therapies on 
the femoral head bone marrow perfusion.   
In addition to that perfusion measuring seems to be a good parameter to identify the 
vitality of bone marrow in regeneration process within bones. So it could be very useful 
for further investigation on this topic.  
It is also of high interest to analyze the bone marrow perfusion in early preoperative 
diagnosis of femoral head necrosis. From the postoperative analysis above we can assume 
a correlation to increased intraosseous pressure, the resulting reduction of intraosseous 
blood supply and a decrease in bone marrow perfusion measuring. The perfusion 
measuring might help to detect very early stages of osteonecrosis and pre-necrotic stages 
as bone marrow edema. The purpose is to detect a possible disrupted perfusion of the 
tissue and to establish thereby a predictive factor which distinguishes between early 
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progressive stages which have the urge to intervene in the destructive process and those 
early precursors which are self-limiting [5].   
As mentioned in the very beginning of this study the natural course of the disease seems 
to progress within two to three years to total joint destruction and the necessity for total 
hip arthroplasty [23].   
Because of that it is important to initiate an effective therapy before there is a stage 
progression or substantial damage of the bone. This would be an important step for 
patients, as joint preserving therapies are only successful when performed on time. To 
support and to prove this idea it is necessary to set up further prospective studies, in 
which bone marrow perfusion measuring is performed on patients with suspected 
osteonecrosis of the femoral head.  
Our work showed that this clinical procedure may bring a great benefit for many patients 
as it could give hints for disturbances of bone marrow perfusion on a very early stage, by 
the administration of a contrast agent in addition to a native MRI.  
As a general conclusion it can be stated that the statistical results of this survey are 
limited, due to the rather small patient collective. Nevertheless, one of the main strong 
points are to show the different application possibilities of modern medicine technology 
developments, like bone marrow perfusion imaging or three dimensional measuring, in 
the field of osteonecrosis.  
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6          Summary and Keywords 
 
Osteonecrosis of the femoral head- a retrospective trial of joint preserving treatment 
options and a prospect to future clinical possibilities. 
Osteonecrosis of the femoral head is a widespread disease which affects mostly young 
and active people. Although there are known risk factors, like steroid intake and alcohol 
abuse the exact pathomechanisms are still unclear. A disturbed blood flow within the 
bone tissue leads to an increased intraosseous pressure, which itself further reduces 
intraosseous circulation. Without therapeutic intervention the necrosis proceeds until total 
hip joint destruction.  In order to avoid early hip arthroplasty in young patients, joint 
preserving therapies are necessary. Mostly common is either a medicamentous therapy 
with the stable prostacyclin analogon Iloprost, to improve circulation within the bone 
leading to a restitution of the necrosis or core decompression with or witout cancellous 
bone grafting. With Core decompression the necrotic area is broken up by drilling into 
the defect zone with small pins, leading to a relief of the intraosseous pressure. Another 
option is autologous cancellous bone grafting. Here the necrotic bone is removed by a 
reamer and replaced by healthy cancellous bone.     
As there are little information in literature about long term results of core decompression 
and cancellous bone grafting we did a follow up survey.  
28 Patients with 32 treated hips with a joint preserving therapy at the Department of 
Orthopedic Surgery, University of Regensburg, during the time from 2006 to 2012 were 
examined according to a clinical protocol with clinical examination, questionnaires and 
radiological imaging with X-ray and MRI. 
The first part of this study is a comparison between 11 patients with core decompression 
and 11 patients after cancellous bone grafting. All of them had an initial ARCO II stage. 
The results showed no significant difference in clinical and radiological aspects four 
(core decompression) or five years (cancellous bone grafting) after the intervention.  
In the second part the precision of the two interventions should be assessed. Therefore a 
3D reconstruction of the necrosis and the drilling channels had been performed from MRI 
images. With the reconstructions it was possible to measure the deviation of the drill 
channel from the center of the necrotic area exactly. It showed that neither in core 
decompression nor in cancellous bone grafting the defect zone had been missed. The 
deviation in both procedures did not differ significantly.  
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As a third part a prospect on the new technology of bone marrow perfusion imaging was 
given. Contrast agent enhanced MRI images are performed at defined moments after the 
application of the contrast agent. With a special ROI (region of interest) measurement it 
is possible to quantify the signal intensity at each measurement. The increase of the signal 
intensity is proportional to the intraosseous perfusion. So it gives a correlation to the 
perfusion in the bone marrow. In this part it could be shown that perfusion imaging is 
feasible in clinical routine. The exact fields of application and its results have to be 
discussed in future surveys.    
 Keywords:  
Osteonecrosis of the femoral head (ONFH), avascular necrosis (AVN), core 
decompression, cancellous bone grafting, joint preserving therapy   
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